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Abstract
Tral is an essential yeast protein required for regulated transcription. Its human
homolog TRRAP regulates factors important in oncogenesis. Mutation of leucine to
alanine at position 3733 in the FATC domain {tral la) results in growth phenotypes
including sensitivity to ethanol. My aim was to examine genetic interactions o f the
FA TC domain o f Tral to define its cellular role. I screened for extragenic suppressors
of the ethanol sensitivity caused by tral la, identifying an opal mutation at tryptophan 165
o f NAM7 as a suppressor. Deleting nam7, upf3, or nmd2 similarly suppressed tra lLA,
thereby linking Tral to nonsense mediated decay. I propose that Tral regulates
transcription o f genes also regulated by NMD. This work emphasizes the importance of
NMD in gene regulation. Furthermore, the cross regulation between Tral and NMD
suggests that mutations in the human NMD machinery may provide a mechanism to alter
pathways influenced by TRRAP in human disease.

Keywords: T ral, TRRAP, SAGA, NuA4, ASTRA, yeast, genetics, transcription,
nonsense-mediated mRNA decay, Nam7, Upf3, Nmd2.
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Chapterl: Introduction
1. Prelude
The 433 kDa protein Tral is a transcriptional regulator found in several protein
complexes in S. cerevisiae. The human homolog o f T ral, TRRAP, regulates transcription
factors required for oncogenesis. T ra l’s role in transcription, presence in multiple
transcriptional regulatory complexes, and membership in the phosphatidylinositol 3kinase-related kinase (PIKK) family o f proteins, suggests that Tral is a key player in
eukaryotic biology. Interestingly, unlike other PIKK family members, Tral lacks kinase
activity. The goal o f the Brandi laboratory is to identify the cellular functions and
molecular interactions of T ra l. The goal o f m y thesis is to examine genetic interactions
o f the FA TC domain o f Tral to gain more information on T ra l’s cellular role.
This introduction will highlight several topics related to gene expression with a
focus on T ral. These topics include: 1) analysis of transcriptional regulation in
eukaryotes using yeast as a model system, 2) the three transcriptional regulatory
complexes that contain T ral; SAGA, NuA4, and ASTRA, 3) the PIKK family of
proteins, o f which Tral is a member, and 4) mRNA processing. Nonsense-mediated
mRNA Decay (NMD) will also be discussed in some detail since the experiments
performed in this thesis suggest that Tral may have a role in this process through its
interactions with the protein Nam7. The theme o f crosstalk between complexes that
include Tral will be evident.

2. Eukaryotic Transcription
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2.1 Yeast as a model organism
Saccharomyces cerevisiae (budding yeast) is a single-celled eukaryote. Many
genes and cellular processes are conserved from yeast to humans, making yeast an
excellent organism for understanding cellular processes, such as transcription, DNA
replication, and protein trafficking in higher eukaryotes. In addition, since yeast stably
exists as a haploid or diploid, it is well suited for classical genetics studies. The entire
yeast genome was sequenced in 1996, making studies on yeast even simpler (Goffeau et
al. 1996). Improved mass spectrometry techniques resulted in a flood of proteins being
characterized, thereby identifying some of the key players involved in important cellular
processes. Increased knowledge o f the cellular processes in yeast will aid in our
understanding of these same cellular processes in more complex eukaryotes, such as
humans.

2.2 Transcriptional Regulation
Transcription is critical for the growth and development of all eukaryotes,
whereby a myriad of protein complexes whose co-ordinated activities are required
(Cairns. 2009). These protein complexes regulate and control transcription so that gene
expression may successfully occur. Diseases, including certain cancers, are a result of
altered gene expression often caused by transcriptional mis-regulation (Villard. 2004).
Transcription requires RNA polymerase II (RNAPII), the General Transcription
Factors (GTFs), and gene specific regulators. The GTFs bind at the promoter through the
action of the TATA-binding protein (TBP) and are directly involved in the recruitment of
RNAPII (Figure 1). The association of GTFs and RNAPII form the pre-initiation
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Figure 1: Eukaryotic transcription is highly regulated. Co-activator complexes
remodel chromatin and direct activators to DNA sequences upstream of the promoter.
Mediator is a co-activator complex mediating protein interactions between the activator
and transcriptional machinery. General Transcription Factors (GTFs) bind at the
promoter through the action of the TATA-binding protein (TBP) and recruit RNA
polymerase II (RNAPII) to the transcription start site. The association of GTFs, TBP, and
RNAPII form the pre-initiation complex (PIC) that allows transcription to begin.

complex (PIC) that allows transcription to begin (Bhaumik et al. 2004, Green. 2005,
Martinez. 2002). Activators are generally sequence specific DNA binding proteins that
bind to a regulatory region on the DNA to activate transcription. An additional set of
molecules generically called co-activators are also involved in regulating transcription
(Figure 1). This class o f molecules can enhance (or sometimes repress) the activity of
activator proteins and/or help the activators function in the context o f chromatin.
Transcriptional co-activator complexes are large protein machines containing multiple
subunits. These co-activator complexes are often recruited to promoters through one of
their subunits, providing activator proteins access to DNA (Martinez. 2002, Naar et al.
2001).

2.3 Chromatin remodeling
Activator proteins must access regulatory sequences on DNA so that transcription
can occur. Highly conserved histone proteins (H I, H2A, H2B, H3, and H4) function as
building blocks to compact eukaryotic DNA. These histone proteins form octamers and
the DNA wraps around the histones to form repeating nucleosomes, the basic unit of
DNA packaging. These nucleosomes then fold into higher order structures to form highly
compact chromatin (Strahl and Allis. 2000). In yeast, a regulatory region is sometimes
“open”, facilitating activator binding to the promoter (Caims. 2009). These constitutively
open promoters are often linked to housekeeping genes. However, if a regulatory region
and promoter is “covered” (located in a region of compact chromatin), chromatin
remodeling is a necessary step to uncover the regulatory sequence and promoter so that
activators can bind (Cairns. 2009). Chromatin-modifying enzymes are required for this
process (Narlikar et al. 2002).
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Generally there are two ways of altering chromatin. Chromatin remodeling
complexes can change the position of DNA wrapped around histones, using ATP
hydrolysis to disrupt histone-DNA interactions, thereby loosening the DNA and making
it more accessible to regulatory proteins (Strahl and Allis. 2000). Yeast and mammalian
SWI/SNF (SWItch/Sucrose NonFermentable) and RSC (Remodels the Structure of
Chromatin) complexes are examples of chromatin remodeling complexes that alter
chromatin structure in this manner (Strahl and Allis. 2000). Chromatin can also be altered
by chromatin modifying enzymes that covalently modify histones in chromatin through
lysine acetylation, lysine and arginine methylation, serine phosphorylation, or
ubiquitination. Modifications occur at specific residues, usually on N-terminal histone
tails (extensions from the histone proteins). These tails provide a surface for interactions
with other proteins (Martinez. 2002, Strahl and Allis. 2000, Daniel and Grant. 2007). The
best studied form of chromatin modification is histone acetylation of lysine residues
catalyzed by histone acetyl transferases (HATs). The simplest interpretation for the role of
histone acetylation is to neutralize the charge on lysine, which weakens the interaction
between DNA and histones, thereby allowing the chromatin to loosen and transcription
factors greater access to DNA (Martinez. 2002, Allard et al. 1999). Histone methylation,
at lysines or arginines, is generally involved in repressing transcription through
condensing chromatin; however, methylation can also loosen chromatin to activate
transcription (Kouzarides. 2002). Histone phosphorylation is generally involved in
activating transcription and is thought to initiate chromosome condensation during
mitosis (Strahl and Allis. 2000). Histone ubiquitination has been linked to both gene
activation and repression (Weake and Workman. 2008).
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Different histone modifications can create specific patterns to attract protein
domains present in various regulators; for example, bromodomains recognize acetylated
lysines and chromodomains recognize methylated lysines (Auger et al. 2008, Keogh et al.
2006). The histone code hypothesis predicts that covalent histone modifications act as
signals to recruit specific protein complexes to DNA to alter transcription and other
downstream cellular events (Strahl and Allis. 2000). Therefore, transcriptional coregulatory complexes contribute to the histone code through modifying chromatin
(Keogh et al. 2006).

3. Transcriptional co-activators containing T ra l
Two large complexes found in yeast, SAGA (Spt-Ada-Gcn5-acetyltransferase)
and NuA4 (Nucleosomal Acetylatransferase of histone H4), are transcriptional co
activator complexes containing multiple subunits involved in altering chromatin and
regulating transcription (Allard et al. 1999, Grant et al. 1997). Homologous complexes of
both SAGA and NuA4 are found in humans, STAGA (Spt3-Taf9-Ada-Gcn5acetyltransferase) and hNuA4 (human NuA4) (Auger et al. 2008, Park et al. 2001).

3.1 SAGA
SAGA is a 2.0 MDa transcriptional co-activator complex containing 19 proteins
that regulate a number of cellular processes, most notably for this thesis, transcription
(Bhaumik et al. 2004, Baker and Grant. 2007). Overall, SAGA is responsible for the
transcription of about ten percent of yeast genes, most of which are involved in stress
response (Lee et al. 2000, Huisinga and Pugh. 2004). Electron microscopy revealed that
yeast SAGA is divided into several modular domains (Figure 2; Wu et al. 2004).
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SAGA

SAGA = Spt-Ada-Gcn5-Acetyltransferase

NuA4

NuA4 = Nucleosomal
Acetylatransferase of histone H4

Figure 2: Tral is a member of SAGA and NuA4 modular protein complexes. SAGA,
determined by electron microscopy, is shown on the left. Tral sits at the periphery of the
complex, made up of modular domains (Figure from: Wu, et al. 2004) NuA4, structure
not yet determined, is also made up of modular domains. Tral is a modular domain and
connects to E afl, a subunit required for assembling the NuA4 complex (Figure from: Lu,
et al. 2009).
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One group of molecules within SAGA is the Spt proteins (Spt3, Spt7, Spt8,
Spt20). The Spt proteins were originally identified by Fred Winston’s laboratory as
suppressors of the transcriptional inhibitory effects caused by Ty transposable elements
in yeast (Winston et al. 1984, Winston et al. 1987). One class of Spt proteins is the
chromatin class and includes the histone proteins. Another class includes those Spt
proteins found in SAGA and also the TATA binding protein (TBP), Spt 15 (Hahn et al.
1989). Spt7 and Spt20 are required for the structural integrity of SAGA (Martinez. 2002,
Wu et al. 2004). Deletions of spt7 or spt20 result in severe phenotypes in yeast (Wu et al.
2004). Spt3 and Spt8 make up the TBP (TATA-binding protein) interaction module
because they facilitate an interaction between SAGA and TBP (Martinez. 2002, Wu et al.
2004). Deletion of either spt3 or spt8 is less severe than that of deletion of spt7 or spt20.
There is another version of SAGA known as the SLIK (SAGA-like) complex (Grant et al.
1998). SLIK contains the same subunits as SAGA, except for Spt8. Therefore, Spt8 is the
only subunit completely unique to SAGA. The SLIK complex, like SAGA, is also
involved in histone acetylation and transcription (Baker and Grant. 2007).
The Ada proteins (Ada2, Nggl/Ada3, Gcn5/Ada4) form the HAT module of
SAGA (Berger et al. 1992, Brandi et al. 1993, Brownell et al. 1996). The ADA genes
were first identified in the Guarente laboratory as suppressors of the toxicity caused by
overexpression of the strong transcriptional activator VP 16 (Berger et al. 1992). Adal is
also part of this group, though it shares more functional similarity with Spt7 and Spt20
since it is required for the structural integrity of SAGA (Martinez. 2002, Wu et al. 2004,
Burgess et al. 2010). Subsequently, function for the Ada proteins in both the activation
and repression of transcription were found (Jacobson and Pillus. 2009). A landmark
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finding in the transcriptional field was the discovery that Gcn5 possesses HAT activity
(Brownell et al. 1996). The Workman laboratory identified the HAT module within
SAGA; Gcn5 being the catalytic subunit and its acetylation of histones H2B and H3
being regulated by Ada2 and Nggl (Grant et al. 1997). Once SAGA is recruited to the
promoter (via T ral, see below) histone acetylation takes place in a targeted fashion,
thereby altering the chromatin landscape for transcription factor recruitment (Martinez.
2002). Interestingly, the Ada proteins also seem to function independently of SAGA, a
point made evident from the fact that a double deletion of both gcn5A and spt7A is more
severe than spt7A alone (Wu and Winston. 2002). This agrees with the finding that Gcn5
also acts in global untargeted acetylation (Imoberdorf et al. 2006). Sgf29 might also be
considered within the Ada group. It is a poorly studied subunit of the SAGA complex,
but it directly interacts with Nggl and shares some of the common phenotypes seen in the
HAT module (Kurabe et al. 2007).
SAGA also possesses histone de-ubiquitylation activity. Histone ubiquitylation is
linked to both gene activation and repression. The DUB (De-UBiquitylation) module in
SAGA consists of: Ubp8, Sgf73, Sgfl 1, and Susl. Ubp8 is the catalytic subunit that
removes ubiquitin from the H2B C-terminal tail, promoting methylation and causing an
increase in active chromatin (Baker and Grant. 2007). Sgf73 physically connects the
DUB module with the rest of the SAGA complex (Koutelou et al. 2010). The Sgf73 and
Susl proteins also link SAGA to the mRNA export machinery (Rodríguez-Navarro.
2009, Koutelou et al. 2010).
SAGA contains many of the TATA-binding protein associated factors (TAFs),
also found within the GTF TFI1D (Transcription Factor II D). TAF9, TAF10, and TAF12
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are all essential genes, perhaps due to their role within both TFIID and SAGA. There is
both a structural and functional conservation between SAGA and TFIID (Martinez.
2002). However, whereas TFIID more globally regulates gene expression, SAGA mainly
regulates gene expression in response to stress (Huisinga and Pugh. 2004).
The final module o f SAGA is composed of the single molecule T ra l. Tral will be
discussed in greater detail below. In this context it is important to note that Tral interacts
directly with transcriptional activators (Baker and Grant. 2007, Brown et al. 2001,
Fishburn et al. 2005, Reeves and Hahn. 2005). As such it is the module that provides one
mechanism to recruit SAGA to promoters.
In addition to its role in transcription activation, SAGA functions in other cellular
processes such as in response to DNA damage, and nucleotide excision repair (Baker and
Grant. 2007). SAGA, through the Gcn5 subunit, is required for normal cell cycle
progression. Gcn5 mutants accumulate at the G2/M phase of the cell cycle (Burgess et al.
2010). Although many SAGA members have been identified, it is still unclear how all of
them interact, coordinate their enzymatic activities, and regulate transcription (Koutelou
et al. 2010).
3.2 NuA4
NuA4 is a 1.3 MDa transcriptional co-activator complex that regulates multiple
cellular processes, including transcription (Allard et al. 1999). NuA4 contains 13 subunits
which make up 5 modular domains. Figure 2 depicts NuA4 and its modular domains (Lu
et al. 2009).
NuA4 exists as both a large 13 subunit complex, and as a smaller complex, known
as piccolo NuA4. The piccolo NuA4 complex forms one module in NuA4 and consists of
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E sal, Yng2, Eaf6, and Epll (Lu et al. 2009). NuA4 acetylates histones H2A, H4, and the
histone variant Htzl through the Esal catalytic subunit (human homolog Tip60) (Lu et al.
2009). Allard et al. demonstrated that Esal can acetylate histones independently,
however, it can only stimulate transcription in the context ofNuA4 (Allard et al. 1999).
Esal is also essential for cell cycle progression in yeast (Allard et al. 1999). NuA4 is the
only essential HAT complex in yeast, perhaps because it acts in multiple pathways (Lu et
al. 2009).
Tral acts to target NuA4 to transcriptional activators, a role it also has within the
SAGA complex. NuA4 is recruited by Tral to the promoter region of many genes, such
as the ribosomal protein genes, to regulate transcription (Auger et al. 2008).
The Eafl subunit is exclusively found within NuA4 (Auger et al. 2008),
functioning as a scaffold module at the centre of the complex. Eafl physically interacts
with and coordinates assembly of the other four modules into NuA4 (Auger et al. 2008,
Mitchell et al. 2008). Eafl has various domains that connect it to the other modules. For
example, the SANT (SWI3-ADA2-N-CoR-TFIIIB) domain of Eafl binds to Tral (Auger
et al. 2008, Lu et al. 2009). The N-terminal region of Eafl associates with the Eaf3, Eaf5
and Eaf7 module, whose function is unclear (Lu et al. 2009). Eaf5 directly interacts with
Eafl, allowing Eaf7 and Eaf3 subunits to associate with the NuA4 complex. EaO, Eaf4,
and Eaf5 also exist as an independent trimer complex (Auger et al. 2008).
Another module consists o f Swc4, A ctl, Yaf9, and Arp4, which are shared
subunits between NuA4 and SWR1, another chromatin remodeling complex involved in
regulating transcription and DNA repair (Lu et al. 2009). Arp4 directly interacts with
Eafl through the HAS (helicase-SANT-associated) domain to connect this module to
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NuA4 (Lu et al. 2009). SWR1 and NuA4 subunits show strong genetic interactions,
which may reflect the cross-talk between these two complexes (Auger et al. 2008). For
example, NuA4 acetylates H4, allowing SWR1 to recognize this acetylation and insert
histone variant Htzl into chromatin. NuA4 subsequently acetylates H tzl, so these two
complexes work together (Keogh et al. 2006, Lu et al. 2009). Interestingly, the human
homolog of NuA4, hNuA4, is an exact physical fusion of SWR1 and NuA4 so only a
single recruitment takes place (Auger et al. 2008).
In addition to its roles in histone acetylation and transcriptional regulation, NuA4
is also involved in chromosome segregation, DNA replication, DNA repair, and cell
cycle progression (Lu et al. 2009). Distinct patterns of histone H4 acetylation by NuA4
are essential in multiple pathways of double-strand break repair, and NuA4 mutants are
sensitive to genotoxic agents causing double strand breaks (Bird et al. 2002). Esal is
needed to acetylate H4 in order for NHEJ (non-homologous end joining), a method of
double strand break repair in which chromosome ends are joined together, to take place
(Bird et al. 2002).
Human NuA4 regulates gene expression by numerous transcriptional regulators,
including E2F1, Myc, and p53 (Lu et al. 2009). Human NuA4, like NuA4 and SWR1, is
involved in DNA repair. In the context of these roles, hNuA4 functions as a tumour
suppressor; interestingly, its expression is reduced in multiple cancer types (Lu et al.
2009).

3.3 ASTRA
The ASTRA (ASsembly of Tel, Rvb and Atm-like kinase) complex is a recently
discovered chromatin remodeling protein complex potentially involved in regulating
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transcription (Shevchenko et al. 2008). All of the components of ASTRA are essential for
yeast viability. ASTRA is composed of the Rvbl/Rvb2 heterodimer, an essential helicase
also present in two other chromatin remodeling complexes, SWR1 and INO80 (Jonsson
et al. 2004). Rvbl and Rvb2 are required for the assembly and function of the INO80
chromatin remodeling complex (Jonsson et al. 2004). In humans, Rvbl/Rvb2 associate
with the transcription factor and oncoprotein Myc, and mutations in Rvbl/Rvb2 prevent
cellular transformation by Myc (Jonsson et al. 2004).
Three less characterized proteins, T til, Tti2, and A sal, are also part of ASTRA
(Shevchenko et al. 2008). Although the functions of Ttil and Tti2 are unknown, they
interact with the telomere binding protein Tel2, another component of the ASTRA
complex. Tel2 is an essential protein, originally identified for its involvement in
regulating telomere length and positioning in yeast, however, it does not do this in
humans (Runge and Zakian. 1996, Takai et al. 2007). Human homologs of Ttil and Tti2
exist with Tel2 as a “Triple T” complex required for DNA damage response (Hurov et al.
2010). Intriguingly, Tel2 physically interacts with and is essential for the stability of all
PI3K-like (PIKK) family members (Takai et al. 2007, Kanoh and Yanagida. 2007,
Horejsi et al. 2010). Tel2 is phosphorylated by CK2 and this phosphorylation is required
for mTOR and SMG1 stability in mouse cells (Horejsi et al. 2010). Since Tel2 is essential
for the stability of all the PIKKs, it is likely an important regulator or coordinator of
PIKK activity. Tel2 preferentially binds to newly synthesized PIKKs (Takai et al. 2007).
Additionally, the interaction between Tel2 and Hsp90 is required for Tel2 to interact with
certain PIKKs such as ATM, ATR, mTOR and DNA-PKcs (Takai et al. 2010).
Furthermore, the interaction between Tel2, Ttil and Tti2 is important for Tel2 function
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(Takai et al. 2010).
Tral is also present in ASTRA. The role o f Tral in the context of ASTRA is
unclear. Perhaps a clue comes from the fact that a triple alanine mutation (tralsRR) at the
C-terminus of Tral results in generation dependent telomere shortening (Mutiu et al.
2007). It is interesting to speculate that this telomere shortening results from T ra l’s role
within ASTRA.

4. Tral/TRRAP
Tral (TRanscription-Associated protein 1) is a 433 kDa essential protein involved
in co-activating transcription through directly binding to acidic activators such as Gcn4,
VP 16, Gal4 and Hap4 (Saleh et al. 1998, Brown et al. 2001). In humans, the homologous
TRRAP (TRansformation/TRanscription domain-Associated Protein) is required for
transcriptional regulation and functions similarly to Tral to recruit STAGA and large
multiprotein HAT complexes to gene promoters (Park et al. 2001). TRRAP regulates
transcription factors, such as Myc, and p53, which are important in oncogenesis
(McMahon et al. 1998, Murr et al. 2007). In addition, TRRAP is required for early
embryonic development and cell cycle progression (Herceg et al. 2001).
TRRAP was first identified as a nuclear protein that interacted with the N-terminus
of Myc and was an essential cofactor for Myc cellular transformation (McMahon et al.
1998). Tral was then identified as the yeast homolog of TRRAP, containing
approximately 55-60 % similarity (McMahon et al. 1998). Yeast Tral was first shown to
associate with SAGA components in 1998 by the Brandi laboratory (Saleh et al. 1998).
Shortly afterwards, the Workman laboratory also identified Tral as a component of both

15

SAGA and SLIK (Grant et al. 1998). Tral was purified as a component of the NuA4
complex by the Côté laboratory in 1999 (Allard et al. 1999).
Tral begins the chain of events leading to transcriptional activation of several
genes. For example, Tral directly binds to the acidic activator Gal4, which is the DNA
binding transcription factor responsible for activating transcription of the GAL genes
(Bhaumik and Green. 2001). The interaction between Tral and Gal4 recruits SAGA to
the upstream activating sequence (UAS), where Gal4 binds (Bhaumik et al. 2004,
Bhaumik and Green. 2001). SAGA then recruits the Mediator complex, which recruits
the GTFs and RNAPII to the promoter to initiate transcription (Bhaumik et al. 2004).

4.1 Structure of Tral/TRRAP
Tral/TRRAP are part of the PI3K-like (PIKK) family of proteins. Figure 3
illustrates the C-terminal domains of T ral. Members of this family are high molecular
mass proteins (300-500 kDa) that are involved in stress response, transcription, DNA
repair, and cell cycle control (Keith and Schreiber. 1995, Abraham. 2004). The amino
terminal domain of PIKK proteins is composed of 40-50 HEAT (Huntintin, Elongation
factor 3, A subunit of protein phosphatase 2A, and Tori) repeats, which may be protein
interaction sites. The catalytic domain o f PIKK family members is a 300 amino acid
phosphatidylinositol-3-kinase (PI3K) domain, which transfers phosphate from ATP to
proteins, rather than lipids (Keith and Schreiber. 1995, Abraham. 2004). The PI3K
domain is flanked by a 500 amino acid FAT (FRAP, ATM, TRRAP) domain upstream,
and directly followed by a 35 amino acid FATC (FRAP, ATM, TRRAP, C-terminus)
domain downstream at the C-terminus (Park et al. 2001, Abraham. 2004). The FAT and
FATC domains, and the large size of these molecules, are unique features of the PIKK
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Figure 3: The C-terminal domains of T ral. Tral belongs to the PIKK family of
proteins. At the C-terminus, members of this protein family contain a FAT domain,
followed by a PI3K domain and FATC domain. The FATC domain normally regulates
the kinase activity o f the PI3K domain. However, the PI3K domain of Tral does not
possess kinase activity.
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family (Bosotti et al. 2000).
Since PIKK family members all have common domains and are involved in
similar processes (stress response), it seems likely that their structure plays a key role in
their function. For example, in the catalytic subunit o f mammalian DNA-dependent
protein kinase (DNA-PKcs), the C-terminal domain of the protein loops back to interact
with N-terminal sequences (Spagnolo et al. 2006). Furthermore, the FATC domain in
other members of the PIKK family, such as mTOR and SMG1, is required for regulating
the kinase activity of the PI3K domain (Takahashi et al. 2000, Morita et al. 2007). The
FATC domain of DNA-PKcs is also required for the kinase activity of PI3K domain
(Priestley et al. 1998, Beamish et al. 2000). Interestingly, the PI3K domain of
Tral/TRRAP is missing the catalytic residues needed for kinase activity (Saleh et al.
1998, Bosotti et al. 2000). However, the conservation of the PI3K/FATC domains across
species implies that the C-terminus of Tral is important for function.

4.2 Mutations of the C-terminus of Tral
As mentioned above, the FATC domain of other PIKK family members is
required for the kinase activity o f PI3K domain. However, Tral/TRRAP does not possess
kinase activity (Saleh et al. 1998). Studies of various mutations in the PI3K and FATC
domains of Tral have shown that these two domains are important for function (Mutiu et
al. 2007, Hoke et al. 2010) Other studies have shown that the C-terminal domains of
some PIKK proteins are involved in protein-protein interactions. For example, the FATC
domain of yeast Mecl (human homolog ATR) interacts with Rfal, thereby recruiting
Mecl to DNA damage sites (Nakada et al. 2005). Another example is the FATC domain
of human ATM is required for the HAT activity and interaction between Tip60 and
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ATM, which is activated by DNA damage (Sun et al. 2005). Mutations in the FATC
domain of ATM abolish the interaction between ATM and Tip60, causing defects in the
DNA damage response pathway (Sun et al. 2005). Likewise, the C-terminus of
Tral/TRRAP may also be involved in protein-protein interactions. One study found that
when the P13K or FATC domain of TRRAP was deleted, it was no longer able to bind to
Gcn5 and recruit HAT activity (Park et al. 2001). Therefore, the C-terminus of TRRAP is
important for the interaction and HAT activity of Gcn5 to occur (Park et al. 2001).
Hence, despite the fact that Tral/TRRAP possess no kinase activity, there is evidence
that the C-terminal domains are important regulators and may be involved in proteinprotein interactions.
A study in the Brandi laboratory performed a targeted mutagenesis in regions of
Tral that may be relevant for function using triple alanine scanning mutations. A PI3K
domain mutant of Tral (tra lSRR) exhibited growth phenotypes such as sensitivity to
ethanol and media lacking phosphate (Mutiu et al. 2007). The tralsRR allele also reduced
/Tgalactosidase activity at the P H 05 promoter. Some of the phenotypes exhibited by
tralsRR are characteristic of SAGA and NuA4 mutants. However, the tralSRR allele also
resulted in shortened telomeres, which may be due to T ra l’s role in ASTRA (Mutiu et al.
2007).
Analysis of mutations in the FATC domain of Tral has shown that the FATC
domain is required for function (Hoke et al. 2010). The Brandi laboratory targeted
residues that were conserved in Tral and among the PIKK family members. They found
that within the FATC domain of T ral, a leucine to alanine change at amino acid position
3733 (tral la) renders yeast sensitive to various conditions of cellular stress, including
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ethanol and temperature extremes (Hoke et al. 2010). In addition, tr a lu changes the
cellular transcription profiles relative to the wild-type allele and results in decreased
protein levels of Tral (Hoke et al. 2010). Like tralsRR, tra lLA showed many severe
phenotypes, some characteristic of SAGA and NuA4 mutants. However, tra lLA did not
show shortened telomeres like tralsRR. Interestingly, a corresponding mutation to tr a lu
in Drosophila SMG1 results in reduced kinase activity of PI3K (Morita et al. 2007).
Therefore, the tr a lu allele was of great interest in elucidating the FATC domain function
of Tral.
A phenylalanine to alanine change at position 3744 at the end of the FATC domain
of Tral {tral fa), also resulted in severe phenotypes and illustrated the importance of the
C-terminus of Tral (Hoke et al. 2010). The tral fa mutation showed severe phenotypes
and reduced viability (Hoke et al. 2010). Like tr a lu , tral fa resulted in transcriptional
changes and growth defects. Furthermore, the Brandi laboratory showed that positioning
of the C-terminus of Tral is important for function, since addition of a glycine to the
terminal amino acid residue in Tral does not support viability in yeast (Hoke et al. 2010).
Although the role of the FATC domain in Tral has not been characterized, evidence
clearly suggests that it is critical for the function of the protein.

4.3 Studies of Tral in Schizosaccharom yces p o m b e
Due to its large size, researchers originally thought that Tral may be a scaffolding
protein, or required for the assembly of SAGA. However, when the 3D structure of
SAGA became available through electron microscopy (Wu et al. 2004), Tral was
revealed at the periphery of the complex (see Figure 2). Hence, this positioning made it
unlikely that Tral was a scaffolding protein. Furthermore, recent studies of Tral in
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Schizosaccharomyces pombe (fission yeast) show that Tral is not needed for the
assembly of SAGA (Helmlinger et al. 2011). In S. pombe, there are two versions of Tral,
Tral and Tra2. Tral is associated with SAGA and ASTRA and is non-essential, whereas
Tra2 is exclusively associated with NuA4 and is essential (Helmlinger et al. 2011).
Interestingly, in a tral A in S. pombe, SAGA is still recruited to some promoters, but not
others (Helmlinger et al. 2011).
Studies of Tral in S. pombe also suggest that T ra l’s function within ASTRA may
be similar to its role in SAGA, since Tral co-purifies with SAGA and several ASTRA
subunits, whereas Tra2 co-purifies exclusively with NuA4 (Helmlinger et al. 2011).
Genetic studies indicate that expression o f many stress response genes that were altered
in tral A, were similarly altered in spt7A and adalA (Helmlinger et al. 2011). More genes
that were also affected by tral A, were not affected by spt7A or adalA, suggesting that
these genes might be controlled by ASTRA or another complex (Helmlinger et al. 2011).
This result emphasizes that T ra l’s role in the context of all the different complexes in
which it is found must be considered. In S. cerevisiae it is possible that Tral is involved
in coordinating the activities of these three protein complexes, or perhaps Tral has
additional roles.

5. PIKK Protein Family
Important cellular regulators such as mammalian ATM, ATR, mTOR, SMG1, and
DNA-PKcs are part of the PIKK family of proteins (Abraham. 2004). PIKKs are relevant
to human health as they are involved in many important cellular processes. ATM and
ATR are involved in cell-cycle checkpoint pathways activated by DNA damage or DNA
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replication stress. Individuals with mutations in ATM can develop a disease called ataxia
telangiectasia, which can also increase the individual’s risk of developing breast cancer
(Ahmed and Rahman. 2006). Another PIKK protein, mTOR, coordinates protein
synthesis, cell growth and cell proliferation with the availability of nutrients and
mitogenic growth factors. DNA-PKcs regulates the repair of DNA double-strand breaks
by the NHEJ pathway. SMG1 is involved in an RNA surveillance mechanism called
nonsense-mediated mRNA decay (NMD), which will be discussed in the next section.
The crystal structure of DNA-PKcs was recently solved (Sibanda et al. 2010).
The N-terminal portion of the protein contains HEAT repeats, which are helix-tum-helix
repeats allowing the protein to bend. The overall form of DNA-PKcs is circular in
structure, with the C-terminal domains, including the FATC domain, sitting at the top of
the protein like a crown (Sibanda et al. 2010). The structure is flexible, allowing for
DNA-double-strand-break repair to occur through the ring (Sibanda et al. 2010). Since
members of the PIKK family are highly conserved, a similar architecture may be shared.
The NMR structure o f isolated FATC domain of yeast Tori has also been solved (Dames
et al. 2005). In the oxidized form, the FATC domain is an alpha-helical structure with a
loop at the C-terminus held together by two conserved cysteine residues. In the reduced
form of Tori, there is more flexibility in this loop structure since the disulfide bond is
broken between the two cysteines (Dames et al. 2005). However, the C-terminus of Tral
lacks these two conserved cysteines, therefore it is possible that the FATC domain
structure is always flexible. Despite Tral/TRRAP’s importance and relevance to disease,
little structure/function information is available.
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6. mRNA P rocessing and N onsense M ediated mRNA Decay (NMD)
During transcription, as the RNA is transcribed by RNAPII, it is subject to
modifications before it leaves the nucleus and ultimately translation in the cytoplasm.
Two modifications that mRNA undergoes is the addition of a 5’ methylguanosine cap to
protect the 5’ end, and 3’ polyadenylation, to protect the 3’ end (Alberts et al. 2010).
These modifications are also key signals for the RNA export machinery as they identify
intact mRNAs to be transported through nuclear pores (Alberts et al. 2010). Splicing and
editing of the mRNA also occurs before it is transported out of the nucleus (Alberts et al.

2010).
The importance o f mRNA turnover in gene regulation has become increasingly
apparent (Gonzalez et al. 2001). Messenger RNAs can be translated or degraded
depending on the cellular situation. Some mutations in mRNA can lead to the insertion of
a premature stop codon, also known as a nonsense mutation (Mitchell and Tollervey.
2003). If translated, nonsense mutations can result in truncated proteins that may be toxic
to the cell. As well as being introduced through errors in transcription by RNAPII,
premature stop codons can result from failure to remove introns or inaccurate
translational starts (Wilusz et al. 2001). To reduce the number of potentially toxic
truncated proteins, all eukaryotes have a process known as nonsense-mediated mRNA
decay (NMD), responsible for degrading mRNAs containing premature stop codons
(Wilusz et al. 2001). In yeast, translation termination is the first step in triggering NMD.
When a stop codon is read by the ribosome during the translation of an mRNA, the
ribosome signals to two translation termination factors, eRFl and eRF3 (Mitchell and
Tollervey. 2003). The next step is to determine whether the translation termination was
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premature. In mammalian cells, where splicing of introns occurs, stop codons over 50
nucleotides upstream of the last exon-exon junction are recognized as premature and get
targeted for NMD (Wilusz et al. 2001). Since yeast generally do not contain introns, the
protein Hrpl recognizes specific sequences in mRNA called downstream sequence
elements (DSE) (Mitchell and Tollervey. 2003). One or more DSE sequences (having the
consensus TGYYGATGYYYY) may be present within one mRNA (Zhang et al. 1995).
eRFl releases the polypeptide chain when a stop codon is read; whether a stop codon is
recognized as premature depends on whether Hrpl is bound to the DSE (Gonzalez et al.
2001). If the stop codon (correct or not) occurs downstream of the DSE sequence, Hrpl
cannot bind to the DSE sequence and the stop codon is believed to be the correct one. If
Hrpl is bound to the DSE and a stop codon is read by the ribosome, a surveillance
complex recognizes the mRNA as containing a premature stop codon, and NMD is
triggered. eRFl then interacts with the NMD surveillance complex (Wilusz et al. 2001).
Figure 4 illustrates the various situations in which mRNA is targeted for NMD.
The NMD surveillance complex consists of three proteins, Nam7, Nmd2, and
Upf3. Mutations in any of the three NMD proteins cause increased translational read
through and stability of mRNA containing premature stop codons (Mitchell and
Tollervey. 2003, Leeds et al. 1991, Cui et al. 1995, Johansson and Jacobson. 2010).
Nam7, a 109 kDa RNA helicase, associates with eRFl and eRF3 during translation
termination, and once the nascent polypeptide is released, eRFl dissociates from the
ribosome and Nmd2, or Upf3, binds the Nam7/eRF3 complex (Gonzalez et al. 2001).
Nam7 binds the prematurely terminated mRNA and targets it for degradation.
Regular full-length mRNAs generally get degraded first by deadenylation of the
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Figure 4: How Nonsense Mediated mRNA Decay (NMD) is triggered. The
downstream sequence element (DSE) is a consensus sequence found towards the end of
the mRNA in yeast. A) When a stop codon is located at the correct position on the
mRNA, the regular peptide is properly translated. B) When a premature stop codon
occurs downstream of the DSE sequence on mRNA, a truncated peptide is translated. C)
When a premature stop codon occurs upstream of the DSE sequence on mRNA, the Hrpl
protein is able to bind to the DSE sequence and recruit the surveillance complex. The
surveillance complex consists of Nam7, Nmd2, and UpG, which trigger NMD.
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poly(A) tail, followed by removal of the 5’ methylguanosine cap and 5’ to 3’ degradation
(Gonzalez et al. 2001). However, prematurely terminated mRNAs are degraded by two
different processes in yeast. In one pathway, the 5’ methylguanosine cap is removed by
the Dcpl/Dcp2 complex, followed by 5’ to 3’ exonucleolytic decay of the mRNA by
Xm l (Gonzalez et al. 2001, Mitchell and Tollervey. 2003). In another pathway,
deadenylation first occurs by Rrp4 and the Ski complex, followed by 3 ’ to 5’
exonucleolytic decay by the Ski complex (Mitchell and Tollervey. 2003). Regardless of
which pathway takes place, both the 5’ and 3’ NMD pathways require the surveillance
complex (Nam7, Nmd2, Upf3) to first recognize these mRNAs as premature. Both
pathways are inhibited in nam7A strains, or by drugs such as cyclohexamide that block
translation (Gonzalez et al. 2001).
The NMD process is highly conserved in all eukaryotes (Mitchell and Tollervey.
2003). NMD is an important process for monitoring these premature stop codons so that
deleterious proteins are not encoded. For example, several forms o f muscular dystrophy
occur due to a truncated or non-functional form of the protein dystrophin caused by a
premature stop codon (Bidou et al. 2004). Therefore, further understanding of NMD is
important for our understanding of diseases.

7. Concluding Rem arks
Although the function of Tral is unknown, its presence in multiple transcriptional
complexes, and as a member of the PIKK. family of cellular regulators suggests it has
important cellular roles. The C-terminus o f Tral is important, as tral la results in severe
growth phenotypes, transcriptional profile changes, and decreased protein levels of Tral.
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Therefore, the majority o f this thesis is based on experiments performed using tr a lu .
The goal of this thesis is to examine genetic interactions o f the FATC domain of Tral to
gain more information on T ra l’s cellular role. My first aim was to identify suppressor
mutations of tra lLA that would link Tral to other molecules and cellular functions. A
suppressor genetics approach was taken, using tra liA. These experiments revealed Nam7
to be a suppressor of tra lLA, linking Tral to NMD. Another suppressor of a second FATC
domain mutant, tra l fA, was revealed to be Tti2, linking Tral to the ASTRA complex. My
second aim was to identify whether the PI3K and FATC domains of Tral interact with
other proteins. A gel filtration experiment suggests that the C-terminus of Tral interacts
with other molecules within the cell.
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C hap ter 2: M a teria ls an d M eth o d s

1. Yeast strains
The Saccharomyces cerevisiae strains used in this study are listed in Table SI in
the Appendix. The MATa strain CY4018 contains a genomic disruption of tral and is
maintained by a full-length plasmid copy of nine-myc (Myc9) tagged traILA expressed
from the DED1 promoter on a URA3 centromeric plasmid (Hoke et al. 2010). The
equivalent MATa strain CY5522 was generated by mating the MATa wild-type TRA1
strain CY4413 with CY4018. After sporulation, a MATa spore colony was isolated that
required the plasmid copy of traliA for growth. Strains carrying tralu and extragenic
suppressors (hereafter defined as es alleles) es2 (CY5579), esl2 (CY5580), es35
(CY5581), es36 (CY5582), es37 (CY5583), es38 (CY5584), es39 (CY5585), es40
(CY5586), es41 (CY5587), es42 (CY5588), and es43 (CY5750) were derived from
CY4018 using the selection scheme described below (Section 3). The MATa equivalents
o f CY5666, CY5758, and CY5603 (es2 tralu, es38 tralu, and es41 tra lu ) were
generated after mating CY5579, CY5584, and CY5587 with CY5522 {tralu)- MATa
spore colonies carrying the suppressor were selected based on their ability to grow at high
temperature and on plates containing 4 % ethanol. Strains CY5688, CY5758, and
CY5691 containing wild-type TRA1 and es alleles es2, es38 and es41 respectively were
generated by plasmid shuffling YCPlac33-7YL47 (CB1617) into CY5579, CY5584, and
CY5587.
Yeast strains deleted for nam7, up/3 and nmd2 were derived from the diploid
consortium strains BY46214, BY44702 and BY41905 (Winzeler and Davis. 1997)
respectively, by selecting kan^ colonies after sporulation. MATa versions of nam7A::kanR
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(CY5932), upf3A\\kax\R (CY5936), and nmd2A::kanR (CY5934) were mated with the
MATa traliA strain CY5967, to yield after sporulation CY5972 (nam7A::kanR trali^),
CY5983 (upf3A\\kanR tral^A), and CY5996 (nmd2A::kanR traliA) strains. Similarly,
CY5933 (MATa nam7A\\kar\R) was mated with CY4400 (MATa tralpA), to yield after
sporulation CY5974 (MATa nam7A:\kan* tralpA)- CY5939 (nam7A ::natR) was obtained
by transformation and integration of a clonNAT marker (Y221) in place of KanMX.
Double mutant strains of nam7A\:natRwith ada2A::kanR (CY5979), eaf3A::kanR
(CY5980), and eaf7A::kax\R (CY5976) were obtained after mating and sporulation of the
diploids o f crosses of CY5939 (nam7A::natR) with BY4282 (ada2A::kanR), BY7143
(eaJ3A::kanR), and BY2940 (eaf7A\\kanR). Yeast transformations of pS14 and pS17
plasmids into strain BY4742 (TRA1 MATa) were performed to create strains CY4486
(Mycg-Nggl) and CY4455 (Mycg-TralpoK/FATc)- pS26 was transformed into strain
BY4742 to create strain CY5766 (Myc9-6HIS -Tralpi3K/FATc)- Yeast transformations were
performed using a standard lithium acetate protocol (Gietz and Woods. 2002).
CE4336 and CE4048 are E. coli strain ER2566 (New England Biolabs)
transformed with pET21a plasmids that allow expression of a 6-H1S tagged GB domain
(a kind gift of Dr. Gary Shaw) and 6-HIS tagged GB domain containing Tralpi3K/FATC
(encoding residues 3290 to 3744 of Tral), respectively.

2. DNA Constructs
The DNA oligonucleotides and constructs used in this study are listed in Tables
S2 and S3 respectively in the Appendix. LacZ reporter PH 05 (CB1503) was previously
constructed (Mutiu et al. 2007). The TRAI (CB1617) allele is on a TRP1 centromeric
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plasmid and was previously described (Mutiu et al. 2007).
A Pstl-SstI fragment containing the MET3 promoter, a Mycg tag, and a portion of
Nggl (CB1997) was cloned into the YEplacl95 multi-copy shuttle-vector plasmid (Gietz
and Sugino. 1988) to create construct pS14 (Myc9-Nggl). A 1442 base pair fragment of
TRA1, starting at nucleotide 9859 and finishing 65 nucleotides downstream of the stop
codon, was generated by PCR amplification using forward primer 5759-1 and reverse
primer 4479-1, incorporating Notl and SstI restriction sites on either end of the piece.
This fragment was cloned into pS14 using restriction enzymes Notl and SstI, replacing
the Nggl fragment with the PI3K and FATC domains of T ral, to give pS17 (MycgTralpoK/FATc)- Oligonucleotides 1880 and 1881 encoding the 6-histidine tag, were 5 ’
phosphorylated with polynucleotide kinase and ligated into the Notl site of pS 17 to create
construct pS26 (Myc9-6HIS-TralpoK/FATc)-

3. Isolation o f tralLA Extragenic Suppressors
Six CY4018 {tral la) 5 mL cultures were grown in YPD (Yeast Peptone Dextrose)
media to stationary phase. One milliliter o f these cultures were frozen (and termed “time
zero”) at -70 °C. Approximately 100 million cells total were plated onto -200 YPD plates
containing 4 % ethanol. These ethanol plates were incubated at 30 °C for 2-5 days. Fast
growing colonies were selected and streaked onto YPD plates containing 4 % ethanol
alongside CY4018. A tral la allele on a TRP1 centromeric plasmid (iB 150) was
transformed into each suppressor strain and the URA3 Cen tra lLA allele in the strains
shuffled out using 5-fluoroorotic acid. All phenotypes were then re-tested, and strains that
retained their ability to grow faster than CY4018 on YPD plates containing 4 % ethanol
were defined as extragenic suppressors {es tralLA)• Oligonucleotide 4292-1 priming
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forward at nucleotide 10687 of TRA1, and reverse primer 5632-1 containing a mismatch
to the leucine codon at nucleotide position 11197-11198 and a match to the alanine
codon, were used to confirm the presence of ira7-L3733A in the suppressor strains.

4. Preparation of Genomic DNA for sequencing
Yeast strains CY4018 (tr a it 4) time zero control, CY5579 (es2 tra lLA), CY5584
(es38 tra lLA), and CY5587 (es41 tra lLA) were grown in 15 mL YPD media to stationary
phase. Cultures were transferred to sterile falcon tubes and cells collected by
centrifugation for 5 minutes at 2000 xg at room temperature. Pellets were suspended in
lmL sorbitol solution (0.9 M sorbitol, 0.1 M Tris-Cl, 0.1 M EDTA, pH 8), transferred to
microfuge tubes, cells pelleted by centrifugation for 4 minutes at 2000 xg , then frozen at
-20 °C for 1 hour. Cells were resuspended in 0.5 mL sorbitol solution containing 100 pL
of 9 mg/mL lyticase and 0.28 M beta-mercaptoethanol, incubated for 110 minutes at 35
°C with slow shaking, and for 10 minutes in a water bath at 37 °C. The resulting
spheroplasts were pelleted by centrifugation at 2000 xg for 5 minutes. Spheroplasts were
resuspended in 0.5 mL TE (10 mM Tris, 1 mM EDTA, pH 8) and 50 pL of 20 % SDS,
and incubated for 30 minutes at 65 °C. Following the incubation, 200 pL 5 M potassium
acetate was added and samples incubated for 30 minutes on ice. Samples were
centrifuged at 12000 xg at room temperature, supernatants transferred to microfuge tubes,
which were then filled with 95 % ethanol. Tubes were inverted, briefly centrifuged, and
supernatant discarded. The resulting nucleic acid mix was suspended in 300 pL of TE (10
mM Tris, 1 mM EDTA, pH 8). Four microlitres o f 50 mg/mL RNase was added to each
tube and incubated for 1 hour at 37 °C. Five hundred microlitres of isopropanol was
added to each tube to precipitate the DNA. DNA was spooled using a sterile needle and

suspended in 200 pL TE. A standard phenol-chloroform extraction was used to purify
DNA (Chomczynski and Sacchi. 1987). Twenty microlitres of 3 M sodium acetate and
500 pL 95 % ethanol was added to each tube. Tubes were centrifuged at 13,000 xg for 3
minutes and the DNA resuspended in 50 pL sterile water. Concentrations of DNA were
measured at OD?6o using a Nanophotometer (Montreal Biotech Inc).

5. Bioinform atic analysis and Identification o f tralLA and tralFA
su p p ressors
Four to nine micrograms of genomic DNA from tralFA time-zero control, and
suppressors es2 tra lLA, es38 trails, and es41 tr a lu were sent to the Centre for Applied
Genomics (Toronto, Ontario) for paired end sequencing using the Applied Biosystems
SOLiD 4.0 next-generation platform. Genomic DNA from a tra lFA control plus 2
extragenic suppressors of tra lFA (discovered by Dr. Chris Brandi) were sequenced in the
same lane. DNA library construction and barcoding was performed at the Centre.
Sequencing results (colourspace data and quality files) were returned for analysis.
The Saccharomyces cerevisiae genome sequence was downloaded from the
Saccharomyces Genome Database (SGD) on March 24, 2011. Custom Shell and Perl
scripts were used for the sequencing analysis. The program Bowtie was used to map the
colourspace reads to each chromosome of the yeast genome and obtain mapped reads in
SAM (Sequence Alignment/Map) format (Langmead et al. 2009). The VCF (variant call
format) from SAMtools was used to obtain a raw list of polymorphisms from the mapped
reads. Reads with a Phred quality score below 20 were eliminated. A custom Perl script
was written to eliminate the background polymorphisms found in wild-type samples
(tra/iA and tralFA). The GenBank file of each yeast chromosome was downloaded from
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SGD on April 12th, 2011 and a custom Perl script was used to assign gene names and
descriptions to each polymorphism. Synonymous substitutions and mutations occurring
in intergenic regions were manually eliminated to identify suppressors. A portion of
NAM7 was PCR amplified using forward primer 6076-1 located at nucleotide 371 of
NAM7, and reverse primer 6076-2 located at nucleotide 622 of NAM7, yielding a 252 bp
PCR fragment.

6. Growth Assays
Yeast strains were grown in 2 mL YPD media or minimal media containing the
appropriate amino acids for plasmid maintenance. Strains were grown at 30 °C to
stationary phase. Five microlitres of each strain was plated in 10-fold serial dilutions on
plates containing varying concentrations of methionine (0 pM, 5 pM, 10 pM, 20 pM),
rich media (YPD), or YPD containing 4 % ethanol, 1.5 pg/mL tunicamycin, 0.075 % tertbutylhydroperoxide, 1 M NaCl, low phosphate, and 2 pg/mL chloramphenicol. Plates
were incubated at 30 °C unless otherwise stated.

7. /?-galactosidase assays
LacZ reporter PH 05 (CB1503) was transformed into yeast strains CY2706,
CY4018, CY5579, CY5584, CY5587, CY5688, CY5690, CY5691 for yS-galactosidase
assays. Strains were grown to stationary phase in 2 mL synthetic dropout (SD) media
lacking leucine. Cells were washed 3 times with 3 mL sterile H20 and resuspended in
200 pL YPD depleted of phosphate. One hundred microlitres of cells were added to 3 mL
of YPD depleted of phosphate. Cells were grown for 16 hours prior to performing the /?galactosidase assay (Han et al. 1988). /Lgalactosidase assays were performed as
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previously described (Hoke et al. 2010, Mutiu et al. 2007).

8. W estern b lot analysis
Yeast strains CY2706 (TRA1), CY4018 (tralLA), and CY5579 (nam7W-sTOP) were
grown in YPD media to OD600 ~2.0. Strains CY4486 (6HIS-GB) and CY4455 (MycgTralpoK/FATc) were grown in both SD media lacking uracil and methionine, or lacking
uracil and containing 20 pM methionine to OD6oo ~2.0. Yeast extracts were prepared by
glass bead disruption as previously described (Hoke et al. 2010). Protein concentrations
were determined using Bradford protein assay reagent (BioRad) and measuring
absorbance using an LKB Ultrospec Plus spectrophotometer (Pharmacia) at 595 nm.
Proteins were separated using SDS-PAGE, transferred to PVDF membranes, and Western
blotting procedures were performed as previously described (Mutiu et al. 2007). The
following antibodies were used: monoclonal anti-c-myc (Sigma) primary antibody at a
1:4000 ratio, monoclonal anti-5HIS (Q1AGEN) primary antibody at a 1:4000 ratio, and
anti-mouse IgG HRP (Promega) secondary antibody at a 1:10000 ratio. Protein signals
were detected using Supersignal West Pico Chemiluminiscent Substrate (Thermo
Scientific).

9. TRA1 mRNA Levels
RNA was extracted from CY4434 (TRA1), CY5967 (tralLA), CY5932 (tra lLA),
and CY5972 {tralLA nam7A) as previously described (Mutiu and Brandi. 2005).
Concentrations of RNA were measured at OD260 using a Nanophotometer (Montreal
Biotech Inc). The High Capacity cDNA RT Kit (Applied Biosystems) was used to obtain

cDNA from the samples following the manufacturer’s instructions. Two-fold serial
dilutions o f 35 ng/pL of cDNA from each sample were prepared and 1 or 2 pL of each
dilution was amplified by PCR. PCR reactions were carried out in 25 pL containing 25
pmol o f each primer, and IX PCR-EZ D-PCR Master Mix Kit (Bio Basic Inc.). PCR
reaction conditions included a 5 minute dénaturation step at 94 °C, and either 25 or 32
cycles with a 45 second dénaturation step at 94 °C, a 45 second annealing step at 54 °C,
and a 1 minute extension time at 72 °C. PCR products were separated by electrophoresis
on a 1 % agarose gel, and visualized under UV light after staining with ethidium
bromide. Forward primer 6108-1 located at nucleotide 72, and reverse primer 6108-2
located at nucleotide 524, were used to amplify a 452 bp portion of the IDH1 gene.
Forward primer 6078-1 located at nucleotide 10309, and reverse primer 4225-1 located at
nucleotide 9711, were used to amplify a 599 bp portion of TRA1.

10. Colony PCR
A small colony from the strain of interest was incubated in a 1.5 mL microfuge
tube with 10 pL of 1 pg/mL lyticase solution in TE (10 mM Tris, 1 mM EDTA, pH 8) for
30 minutes at 37 °C, followed by a 20 minute incubation at 95 °C. The tubes were
centrifuged for 10 minutes at 13,000 xg and 1 pL of the supernatant was used in the PCR.
PCR mixtures (total volume 25 pL) contained 1 pL of DNA (supernatant), 13.8 pL sterile
H20 , 5 pL 5X GoTaq® Flexi buffer (Promega), 2 pL 2.5 mM dNTP mix (Promega), 1.5
pL 50 mM MgCl2 (Promega), 0.2 pL of GoTaq® Flexi Taq DNA polymerase
(Promega), and 1 pL of 25 pmol of each primer. PCR reaction conditions included a 5
minute dénaturation step at 94 °C, and 25 cycles with a 45 second dénaturation step at 94
°C, a 45 second annealing step at 54 °C, and a 1 minute extension time at 72 °C. PCR

35

products were separated by electrophoresis on a 1 % agarose gel, and visualized under
UV after ethidium bromide staining to check for the desired band.

11. Gel Filtration Chromatography
Yeast strain CY5766 (Mycc>-6HIS -TralpoK/FATc) was grown in SD media lacking
uracil and methionine to OD6oo ~2.0. Cells were pelleted at 4 °C and washed in P 0 4
Buffer 150 (50 mM P 0 4 pH 7.4, 150 mM NaCl). Yeast extract was prepared by grinding
in liquid nitrogen as previously described (Hoke et al. 2010). Cell lysate of E. coli
CE4048 (6HIS-GB) was prepared as described in the phage display section (see below),
except P 0 4 Buffer 150 was used. Protein concentrations were determined using the
Bradford assay (BioRad). Sephadex® G-75 gel filtration beads were hydrated in TE (10
mM Tris, 1 mM EDTA, pH 8) at 90 °C, and equilibrated with P 0 4 Buffer 150. Five
hundred micrograms of protein was loaded onto 500 pL hydrated Sephadex® G-75 gel
filtration beads in spin columns, washed four times with P 0 4 Buffer 150, and fractions
collected after each wash by centrifugation at 2000 xg for 1 minute. Twenty microlitres
of each fraction was loaded onto two 10 % SDS-PAGE gels, transferred to PVDF
membranes, and Western blotted as described above.

12. Phage D isplay
E. coli strains CE4336 (6HIS-GB) and CE4048 (6HIS-GB-Tralpi3K/FATc) were
grown in 1 L LB media containing 100 pg/mL ampicillin at 37 °C to an OD60o ~ 0.9.
Cells were induced with 1 mM isopropyl (3-D-l-thiogalactopyranoside (IPTG) for 4 hours
at 15 °C. Cells were pelleted, washed with P 0 4 Buffer 200 (50 mM P 0 4, pH 7.4, 200 mM
NaCl, 10 % glycerol), re-suspended in 30 mL P 0 4 buffer 200, and stored at -70 °C
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overnight. Cell suspensions were thawed on ice and protease inhibitors (1:100 BTI, 1:100
PMSF, 1:1000 leupeptin, 1:1000 pepstatin) added. Cells were homogenized using a
dounce homogenizer for 5 minutes on ice, followed by lysis using a mechanical
EmulsiFlex C homogenizer (Avestin). Cell lysates were collected by centrifugation for 25
minutes, 30000 xg at 4 °C. Each lysate was incubated with a 50 % IgG sepharoseIM 6
Fast Flow (Amersham Biosciences) resin slurry (equilibrated in PO4 buffer 200 with
protease inhibitors) for 90 minutes rotating at 4 °C. Resins were centrifuged at 1000 xg at
4 °C for 2 minutes and the unbound fractions collected. IgG sepharose resins were
incubated with 5 mg/mL BSA in TBS-T (0.5 % Tween20 in 50 mM Tris-Cl, 150 mM
NaCl, pH 7.5) for 5 minutes. The resins were then equilibrated with TBS-T to prepare for
phage display.
Phage display was performed using the Ph.DIM-12 Phage Display Peptide Library
Kit (NEB) as described by the manufacturer, with the following modifications. The phage
library was incubated with 6HIS-GB IgG beads for 30 minutes rotating at 4 °C and the
unbound phage collected. Unbound phage were transferred directly to 6HIS-GBTralpoK/FATC IgG beads and incubated for 30 minutes. The 6HIS-GB-TralPi3K/FATC
column was washed 12 times with TBS-T, and phage eluted by the addition of 1 mL
Elution buffer (0.2 M glycine-HCl, pH 2.2, 1 mg/mL BSA). Following a 25 minute
incubation at 4 °C, 150 pL of 1 M Tris-HCl, pH 9.0 was added. Eluted phage were
amplified in E. coli strain ER2738 and precipitated using 20 % PEG/2.5 M NaCl. Phage
were titered as described in the Ph.D.IM Phage Display manual (NEB) and five
subsequent panning rounds were performed. Blue plaques were chosen after the final
panning round and sequenced as described in the manual. Once phage were eluted from
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both 6HIS-GB-Tralpi3K/FATC and 6HIS-GB, IgG beads were suspended in 200 pL IX
Laemmli buffer (63 mM Tris HC1, 10 % Glycerol, 2 % SDS, 0.0025 % Bromophenol
Blue, pH 6.8) and heated at 65 °C for 10 minutes to elute proteins.
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C hapter 3

1. Rationale
Tral/TRRAP are members of the PI3K-related kinase (PIKK) family of proteins,
a group of molecules that function as key cellular regulators in diverse pathways.
Members of this protein family contain a phosphatidylinositol-3-kinase (PI3K) domain
followed by a FRAP-ATM-TRRAP C-terminus (FATC) domain at the C-terminus. The
FATC domain in other members of the PIKK family is required for regulating the kinase
activity of the PI3K domain (Takahashi et al. 2000, Morita et al. 2007). Interestingly, the
PI3K domain of Tral/TRRAP does not possess the kinase activity found in other
regulators in the PIKK family (Saleh et al. 1998), therefore making the question of the
function of the PI3K and FATC domains of Tral/TRRAP very intriguing.
The high degree of conservation of the P13K/FATC domains across species
implies that the C-terminus of Tral is important for function. Indeed, mutagenesis studies
have clearly shown that both the PI3K and FATC domains are important (Mutiu et al.
2007, Hoke et al. 2010). A triple alanine scanning mutation in the PI3K domain of Tral
(tralsRR), results in phenotypes such as ethanol and temperature sensitivity and shortened
telomeres. A phenylalanine to alanine change at position 3744 at the end of the FATC
domain of Tral (tral fa) results in severe phenotypes and illustrates the importance of the
extreme C-terminus of Tral (Hoke et al. 2010). Furthermore, addition of a terminal
glycine at the end of the FATC domain results in loss of viability in yeast, illustrating that
precise positioning o f the C-terminus of Tral is important for function (Hoke et al. 2010).
Although the role of the FATC domain in Tral has not been defined, it is clearly critical
for the function o f the protein.
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An alignment of the FATC domains of Tral from various species, and from other
members of the PIKK family (Hoke et al. 2010) illustrates that leucine at position 3733 is
conserved throughout the entire PIKK family. When this leucine is mutated to alanine
(tra lu ), yeast are sensitive to various conditions of cellular stress, including ethanol and
temperature extremes. In addition, tral la changes the cellular transcription profiles
relative to the wild-type allele and results in decreased protein levels of Tral (Hoke et al.
2010). Consistent with this protein being critical for function, an equivalent mutation to
tral la in Drosophila SMG1 reduced kinase activity of the adjacent PI3K domain (Morita
et al. 2007). Therefore, this tral la mutation was of great interest in elucidating the
function o f Tral.
Isolation o f extragenic suppressor mutations of tral la provides a powerful
approach to indicate intermolecular interactions, regulatory proteins, and parallel
pathways that the FATC domain is involved. A genetics approach was taken to avoid any
bias in determining function and because of the ease of genetics in the yeast system.
Furthermore, the costs o f whole-genome sequencing have decreased in the past few
years, further facilitating this approach. For this chapter, suppressor genetics was used to
identify and characterize extragenic mutations that suppress phenotypes caused by tral laM y aim was to identify suppressor mutations o f tral la that would link Tral to other
molecules and cellular functions.
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2. Results
2.1 Extragenic Suppressors partially restore growth defects of tra lm
Tral contains a FATC domain at its C-terminus. A leucine residue at the position
equivalent to 3733 of Tral is conserved throughout the FATC domains of the entire
PIKK family, as shown in Figure 5. When this leucine is mutated to alanine (tralLA), the
resulting yeast strain is sensitive to ethanol and temperature extremes, shows
transcriptional defects at the P H 05 promoter, and reduced protein levels of Tral (Hoke et
al. 2010). Therefore, tralla was used to discover extragenic suppressor mutations that
may reveal clues into the functions o f Tral.
Potential extragenic suppressors were initially isolated by plating yeast strain
CY4018 {tral la) on YPD plates containing 4 % ethanol. Since CY4018 grows slowly on
4% ethanol plates, I selected for colonies that grew quickly on these plates. Forty three
colonies were initially identified. O f these, 11 grew faster than CY4018 on a second
screening on 4 % ethanol plates. The suppressor mutations were confirmed to be
extragenic by plasmid shuffling. A tral la allele on a TRP1 centromeric {CEN) plasmid
(iB 150) was transformed into each suppressor strain and the URA3 CEN tral la allele
shuffled out using 5-fluoroorotic acid. All 11 strains containing extragenic suppressor
mutations, retained their ability to grow faster than CY4018 on 4 % ethanol plates, with
each suppressor allele tentatively referred to as es2, esl2, es35, etcetera. Furthermore, the
presence of tral la in the suppressor strains was confirmed by colony PCR analysis.
Primers 4292-1 and 5632-1 (containing a mismatch to the leucine codon and match to
alanine) were used to generate a 512 bp product for tral alleles that contained the
L3744A mutation (Figure SI, Appendix).
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Figure 5: Trai FATC domain alignment showing location of trai la mutant (Figure
from: Hoke et al. 2010). The trai la mutation is positioned at a leucine residue (position
3733 in S. cerevisiae T rai) that is conserved throughout the entire PIKK family.
Sequences of Saccharomyces cerevisiae T rai, Schizosaccharomyces pombe Tra2,
Schizosaccharomyces cerevisiae T rai, Neurospora crassa T rai, Drosopihila
melanogaster Nipped-A, and Homo sapiens TRRAP were aligned, shown in the top panel
(Hoke et al. 2010). Sequences of Saccharomyces cerevisiae T rai, Tori, Homo sapiens
TRRAP, ATR, DNA-PKes, and SMG1 were aligned, shown in the bottom panel (Hoke et
al. 2010).
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Figure 6 shows the growth of the 11 original strains containing extragenic
suppressor mutations (es trai la) on YPD plates containing 4 % ethanol, or grown at 37
°C compared to CY2706 {TRAI) and CY4018 {trai la)- All 11 strains containing es
mutations grew faster than CY4018 {trai la) under these selective conditions, though
slower than CY2706 {TRAI). Although subsequent experiments were performed using all
11 suppressor mutations, only es2 tra lLA, es38 tra lLA, and es41 trai la were eventually
sent for whole-genome sequencing, so the results presented in this thesis are focused on
these three suppressors.
Growth assays were performed using a variety o f conditions to explore which of
the phenotypes displayed by tralLA are alleviated by the extragenic suppressors. I also
wanted to determine whether suppressor mutations in the context of wild-type TRAI {es2
TRAI, CY5688; es38 TRAI, CY5758; es41 TRAI, CY5691) would display any
phenotypes (Figure 7). Strains containing extragenic suppressor mutations {es tralLA)
partially suppressed slow growth due to trai la on YPD plates containing 4 % ethanol, 1.5
pg/mL tunicamycin, 0.075 % tert-butylhydroperoxide, and grown at 37 °C. The ethanol,
tunicamycin, and tert-butylhydroperoxide sensitivity are characteristic phenotypes of
other SAGA mutants. Partial suppression was also seen on YPD containing low
phosphate, which is an indicator of defects in inducing P H 05 genes. No suppression was
seen on YPD containing 2 pg/mL chloramphenicol. Interestingly, strains containing es
trai la grew faster than CY2706 {TRAI), CY4018 {trai la)-, and strains containing the es
suppressor mutations in the context of TRAI on 1 M NaCl. In the context of TRAI the es
suppressor mutations resulted in similar or slower growth as compared to the wild-type in
the conditions assayed. CY5691 {es41 TRAI) grew slower than CY2706, CY5584 {es2
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YPD
TRA l
tra lu
es2 tra lM
e sl2 tra l^
es35 tral U
es36 tral la
es37 tral la
es38 tral la

YPD

YPD + 4 % EtOH

YPD at 37 °C

TRA1
tral la
es39 tral la
es40 tral la
es41 tralLA
es42 tral la
es43 tral la

Figure 6: Original Extragenic Suppressors (es) of tra lLA. Growth of CY2706 ( TRA1),
CY4018 (tralLA), and strains containing extragenic suppressor mutations (es) and CEN
plasmids expressing tral la were compared. Strains were grown to stationary phase and
plated in 10-fold serial dilutions on rich media (YPD), and YPD containing 4 % ethanol
or grown at 37 °C. Plates were incubated at 30 °C unless otherwise stated.

44

YPD

4% EtOH

Tunicamycin

tBOH

NaCI
TRAI
tra lLA
es2 tra lLA
es2 TRAI
es38 tra lLA
es38 TRAI
es41 tra iM
es41 TRAI

Figure 7: Three Extragenic Suppressors (es) of tra lLA. Growth of CY2706 {TRAI),
CY4018 {tralLA), three strains with extragenic suppressor mutations containing CEN
plasmids expressing tralLA CY5579 {es2 tralLA), CY5584 {es38 tralLA), CY5587 {es41
tralLA), and three strains with extragenic suppressor mutations containing CEN plasmids
expressing TRAI CY5688 {es2 TRAI), CY5690 {es38 TRAI), and CY5691 {es41 TRAI)
were compared. Strains were grown to stationary phase and plated in 10-fold serial
dilutions on rich media (YPD), or YPD containing 4 % ethanol, 1.5 pg/mL tunicamycin,
0.075 % tert-butylhydroperoxide (tBOH), 1 M NaCI, low phosphate, 2 pg/mL
chloramphenicol, and YPD at 37 °C.
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TRA1) and CY5587 (es38 TRA1) on YPD containing 1.5 pg/mL tunicamycin or 0.075 %
tert-butylhydroperoxide. Taken together, these results suggest that the extragenic
suppressor mutations (es) partially restore some of the growth defects observed by tra liA.

2.2 Extragenic Suppressor mutations partially restore transcriptional defects of
t r a l LA

Since suppressor mutations partially restore slow growth resulting from tralLA
under stress conditions, I addressed whether they restore transcription defects associated
with tra lLA■tral la decreases expression of a PH05-LacZ reporter (Hoke et al. 2010).
Expression from the P H 05 promoter using a LacZ fusion was determined in CY2706
(TRA1), CY4018 (traliA), the es tral la strains, and the es TRA1 strains.
As shown in Figure 8, the es alleles partially restore transcriptional activation of
PH 05-LacZ in the context of tr a lu by approximately 2-fold. The effects of the
suppressors on transcription followed a similar pattern to their suppression of traliA *
growth defects on low phosphate plates. Strains containing suppressor mutations grew
faster than CY4018 (tral la) on low phosphate YPD plates, but not as fast as CY2706
(TRA1). The ability of the suppressor mutations to suppress the transcriptional defects of
tralLA is thus partial. Interestingly, the strains with the extragenic suppressors in a wildtype TRA1 background {es TRA1) showed a 50% decrease in transcription (compared to
the wild-type strain). The transcriptional activity of tralLA is about 25 % of es2 TRA1,
es38 TRA1, and es41 TRA1, whereas the transcriptional activity of tralLA extragenic
suppressors {es tralLA) is about 50 % of es2 TRA1, es38 TRA1, and es41 TRAl.
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Figure 8: y?-galactosidase Assay, ^-galactosidase activity o f wild-type Tral (TRA1),
leucine 3733 to alanine mutant (tra lLA), three extragenic suppressor mutations containing
centromeric plasmids expressing tral la (es2 tral la, es38 tral la, es41 tral la), and the
three extragenic suppressors containing centromeric plasmids expressing TRA1 (es2
TRA1, es38 TRA1, es41 TRA1) were compared under the PH 05 promoter, figalactosidase activity was determined after growth in low phosphate media for 16 hours
at 30 °C. Samples were performed in triplicate, and the standard deviation is shown.
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2.3 Extragenic suppressors are recessive and belong to three complementation
groups

Classical genetic approaches were used to determine if the suppressor mutations
were single genes, acting dominantly or recessively, and to determine the number of
complementation groups. MATa haploid strains CY5579 (es2 tralLA), CY5584 (es38
tra l la), and CY5587 (es41 tra l la) were mated with MATa haploid CY5522 (tralLA) to
produce diploid strains homozygous for tralLA and heterozygous for each suppressor. In
this manner, I could determine whether suppressors were dominant or recessive. Figure 9
shows that the diploid strains, heterozygous for each of the suppressor mutations, grow
slowly on 4 % ethanol and at 37 °C. Therefore, the suppressor mutations were recessive,
indicating that a loss o f function allele likely caused the suppression.
Since suppressors were recessive, complementation groups could be determined
by mating the suppressor strains. Figure 10 shows the complementation group
determination for es2 tral la- MATa haploid strain CY5579 (es2 tra lLA) was mated with
the MATa version (CY5666) to produce a diploid strain homozygous for es2 tra lLA- As
expected for the es2 suppressor mutation, the diploid homozygous for es2 grew faster
than the diploid heterozygous for es2 on a YPD plate containing 4 % ethanol. Similarly,
MATa CY5666 (es2 tralLA) was mated with MATa CY5584 (es38 tral la) and CY5587
(es41 tral la) to check for complementation. Both the es38/es2 and es41/es2 diploids
grew slowly on a YPD plate containing 4 % ethanol (Figure 10), demonstrating that es2
is in a separate complementation group from es38 and es41. Similar matings were
performed for all 11 haploid strains containing tral la extragenic suppressor mutations
and three complementation groups were found (results not shown). One complementation
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TRA1 x TRA1
fraJLAx trallA
trallA xes2 tralLA
tralLA x es38 tralLA
tralLA x es41 tralLA

Figure 9: Genetics test of extragenic t r a l LA suppressors. Growth of wild-type diploid
(TRA1 x TRA1), leucine 3733 to alanine diploid (tr a lu x tralLA), and three diploid
extragenic suppressors (homozygous for tralLA and heterozygous for each suppressor
es2, es38, and es41) were compared. Strains were grown to stationary phase and plated in
10-fold serial dilutions on rich media (YPD), and YPD containing 4 % ethanol or grown
at 37 °C. Plates were incubated at 30 °C unless otherwise stated.
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TRA1 x TRA1
tra lLAx tra lLA
tra lLAxes2 tra lLA
es2 tra llAx es2 tra lLA
es2 tra llA x es38 tra lLA
es2 tra lLAx es41 tro lLA
Figure 10: Complementation group of es2 suppressor. Growth of wild-type diploid
(TRA1 x TRA1), leucine 3733 to alanine diploid (traliA x trahA), heterozygous
suppressor (es2 tralLA x tral lA), and diploid extragenic suppressors (homozygous for
traliA and heterozygous for two suppressors) were compared. Strains were grown to
stationary phase and plated in 10-fold serial dilutions on rich media (YPD), or YPD
containing 4 % ethanol. Plates were incubated at 30 °C.
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group consisted o f es2, a second of es35, and a third group comprising the remainder of
the suppressors.
Since es2 partially suppressed the transcriptional defects of tralLA, and was the
only one in its complementation group, genomic DNA extracted from the CY5579 strain
was sent for whole-genome sequencing. Although es35 was also in its own
complementation group, its DNA was not sent for sequencing because it did not restore
transcription at the P H 05 promoter (results not shown). es38 and es41 were in the same
complementation group. Both were sent for whole-genome sequencing to increase the
chances of identifying the mutation. DNA from the CY4018 (trail, a) time zero control
was also sent for sequencing to identify mutations in the parent strain background.

2.4 Analysis of whole-genome sequencing data and identification of suppressors
A total o f 15 samples were sent to the Centre for Applied Genomics for paired
end sequencing using the Applied Biosystems SOLiD 4.0 next-generation platform. DNA
from the tra lLA time zero control was sent along with es2, es38, and es41. As mentioned
in the introduction, a mutation at the end o f the FATC domain of Tral (tra lFA) also
results in growth phenotypes and transcriptional defects (Hoke et al. 2010). Therefore, a
control strain containing tra lFA plus 2 extragenic suppressors of tra lFA (isolated by Dr.
Chris Brandi) were sequenced in the same lane. Seven additional samples came from Dr.
Ivan Sadowski (University of British Columbia) and one from Dr. Greg Gloor. Figure 11
outlines the method used for analyzing the whole-genome sequencing data. Sequencing
results (colourspace data and quality files) were returned, and the Saccharomyces
cerevisiae genome was downloaded from SGD. There were approximately 50 million
sequencing reads for each sample. The program Bowtie was used to map the colourspace
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Downloaded Colorspace
Sequencing Data

Downloaded S. cerevisiae
genome

Used Bowtie to map
reads to genome

Used SAM tools VCF
(Variant Call Format) to
identify polym orphism s

Raw list of polymorphisms
T

List of polymorphisms

Filtered out polym orphism s
with a Phred score <20

Wrote Perl script to eliminate
polymorphisms found in wild type sequence
Downloaded feature
table from SGD

Used Perl script to obtain
description of all polymorphisms

mmmmi

Manually parsed through data |
eliminating mutations in
intergenic regions and
synonymous mutations

Figure 11: Identification of Extragenic Suppressor mutations using Bioinformatics.
This flow-chart describes the analysis o f ABI SOLiD 4.0 colourspace sequencing data to
identify tr a lu and tr a lfA extragenic suppressor mutations.
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sequencing reads to each chromosome o f the yeast genome, and obtain mapped reads in
SAM format (Langmead et al. 2009). Bowtie mapped approximately 60 % of the
sequence reads from each sample to the yeast genome. Forward and reverse reads were
mapped separately because more coverage was obtained in this manner, as opposed to
mapping them as paired-ends. The “v - 3” alignment mode from Bowtie was used,
allowing reads with a maximum o f 3 mismatches to be mapped to the genome (Figure
S2).
Each mapped read was output in SAM format. A raw list of polymorphisms was
compiled using the variant call format (VCF) from SAMtools. Polymorphisms with a
Phred score greater than 20 were filtered into a new file and further analyzed. A Phred
score of 20 was chosen because this insures that the polymorphism occurs 99 % of the
time in the sequences. A custom Perl script was written (Figure S3) to eliminate the
background polymorphisms found in the parent strains (tralLA and tralFA) from
suppressors. Only polymorphisms that were unique to a particular complementation
group were examined.
The GenBank file of each yeast chromosome was downloaded from SGD and a
custom Perl script used to assign gene names and descriptions to each polymorphism
(Figure S4). Synonymous substitutions and mutations occurring in intergenic regions
were eliminated from the analysis. The es2 mutation that suppressed tralLA was a UGG
(encoding tryptophan) to UGA (opal) mutation in the NAM7 gene at codon 165 (nam7w_
um).

Nam7 is a protein involved in mRNA decay. The mutation that suppressed tralFA

was a T to C transition in codon 328 of 7772, converting the codon from TTT
(phenylalanine) to TCT (serine). Tti2 is a component of the ASTRA complex. There was
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only one candidate suppressor for the es38 and es41 complementation group and this was
a G to A transition in codon 39 of SRB6, converting the codon from GGT (glycine) to
GAT (aspartic acid). SRB components are part of Mediator and they are needed for
transcription of most genes in vivo (Martinez. 2002). After sequencing the SRB6 gene
however, I found that it was in fact a background mutation. Therefore, no suppressors
were identified for the es38 and es41 complementation group.
To confirm that the nam7W-uM allele segregated with the suppression phenotype,
CY5579 (es2 tra lLA) was mated with CY4018 (tralLA), the resulting diploid sporulated,
and spore colonies tested for growth on YPD plates containing 4 % ethanol. DNA was
extracted from four colonies exhibiting slow growth on 4 % ethanol (believed to be
NAM7 tr a lu ) and four colonies exhibiting faster growth than CY4018 (tral la) on 4 %
ethanol (believed to be suppressor nam7 w-um)- A portion of NAM7 was PCR amplified
and sequenced. All strains exhibiting slow growth on 4 % ethanol contained wild-type
NAM7\ all strains exhibiting faster growth than CY4018 on 4 % ethanol contained
nam7W-uM- Therefore, the es2 suppressor mutation was confirmed to be nam7W-uM-

2.5 Suppressor n a m 7 W-uMhelps restore tralLA protein levels
Since tralLA decreases tral la protein levels (Hoke et al. 2010), it is possible that
naw7^.f;A/acts by increasing tralLA protein levels. Western blotting was used to
determine the amount of tralLA in yeast extracts from CY2706 (TRA1), CY4018 (tral la),
and suppressor CY5579 (nam7w-UM)• Tral was N-terminally Mycg-tagged in all samples,
and proteins separated using SDS-PAGE (Figure 12). A band corresponding to ~433 kDa
(Tral) was present in all samples, tral la showed reduced protein levels of tralLA as
compared to TRAl. The extragenic suppressor nam7w-uM increased the amount o f tralLA■
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Figure 12: Tral protein levels in the presence of n am 7W-uM> Cell lysates were prepared
by bead lysis from CY2706 (Myc9-Tral), CY4018 (Mycg-tral LA), and CY5579 (MyC9tralLA, nam7W-uM)- Sixty micrograms (lanes 1, 3, and 5) and 30 pg (lanes 2, 4, and 6) of
protein was separated by SDS-PAGE on a 5 % gel, transferred to a PVDF membrane, and
probed with an a-myc antibody. The bottom half of the gel was stained with Coomassie
Brilliant Blue (CBB).
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Therefore, the nam7W-uM suppression of tral la may occur through restoration o f tr a lu
protein levels.

2.6 Deletions of NMD components nam 7, upf3, and nm d2 suppress traliA
Since the traliA suppressor was a tryptophan (W) to opal mutation in the NAM7
gene (nam7w-uM), it was possible that nam7A would also suppress defects exhibited by
tral . Suppression by nam7A would be consistent with the suppressor being recessive
l a

and a loss of function mutation. Furthermore, since Nam7, UpO, and Nmd2, are
components of the NMD machinery, I tested whether upf3A and nmd2A would also result
in suppression of tralLA. Growth assays were performed on YPD plates containing 6 %
ethanol or grown at 37 °C to test whether nam7A, upf3A, and nmd2A, would suppress the
growth defects seen by tra lLA. Six percent ethanol was used (rather than 4 %) because the
consortium strain background is less sensitive to ethanol. Figure 13 shows that CY5972
(tralLAlnam7A), CY5983 (tralLAlupf3A), and CY5996 (tralLA/nmd2A) grow faster than
CY5967 (tralLA) on 6 % ethanol, though equivalent to CY5967 on YPD at 37 °C.
Therefore nam7A, upf3A, and nmd2A suppress the ethanol, but not the temperature,
sensitivity phenotypes associated with tralLA-

2.7 TRA1 mRNA levels appear to be unchanged in tralLA, nam7A, and tralLA nam7A
Nam7 is part of the surveillance complex involved in nonsense mediated mRNA
decay (NMD). Since the tralLA suppressor nam7A helps recover tral la protein levels,
perhaps nam7A stabilizes TRA1 mRNA. RNA was extracted from CY4434 (TRA1),
CY5967 (tral la), CY5932 (nam7A), and CY5972 (tralLA nam7A) strains to investigate
whether there were differences in expression. Two-fold serial dilutions o f 35 ng/pL of
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Figure 13: Growth assays testing suppression of tralLA by nam 7A , upf3A , and
nm d2A. Growth o f CY4434 (TRA1/NAM7), CY5967 (tral la/NAM7), CY5932

(:TRAllnam7A), CY5972 (tralLA/nam7A), CY5936 (TRAl/upf3A), CY5983
(tralLA/upf3A), CY5935 (TRAl/nmd2A), and CY5996 (tralLAlnmd2A) haploids were
compared. Strains were grown in YPD media to stationary phase, and 10-fold serial
dilutions were plated onto rich media (YPD), YPD containing 6 % ethanol, or YPD
grown at 37 °C. Strains were grown at 30 °C unless otherwise stated.
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cDNA from each sample were prepared and 1 pL (IDH1) or 2 pL (TRA1) of each dilution
was amplified by PCR. IDH1 was used as a control because previous gene expression
studies (Hoke et al. 2010) indicated that IDH1 mRNA was unchanged by the tralLA
mutation. Figure 14 qualitatively shows that the relative levels of mRNA between TRA1
and IDH1 are unchanged. Unfortunately the intensity of the bands was not sufficient to
allow quantitation. Therefore, the ratios of THAI mRNA and 1DH1 mRNA were
qualitatively compared. The relative band intensities observed in the TRAl cDNA
amplifications (Figure 14A) mirror the band intensities seen in the IDHI control
amplifications (Figure 14B). Figure 14C shows a PCR water control, a negative control
(no RNA), a positive control (amplification of TRAl), and the no reverse transcriptase
controls for each sample. Bands were absent in the no RT controls, indicating that the
RNA samples were free of genomic DNA. Therefore, these initial results suggest that
TRAl mRNA levels are comparable between TRAl, tr a lu , nam7A, and tralLA nam7A.
However further experiments should be performed to quantify these initial results.

2.8 nam 7A suppressed tralFA but not deletions of SAGA or NuA4 components

I tested whether nam7A would suppress another FATC domain mutation, tralpA,
and deletions of the SAGA component ada2 or NuA4 components eaf3 and eaf7. Growth
assays were performed on YPD plates containing 6 % ethanol, 6 % ethanol grown at 35
°C, or YPD grown at 37 °C. CY5974 {nam7A!tralfa) grows faster than CY4400 ( tralpA)
on YPD plates containing 6 % ethanol and grown at 37 °C (Figure 15). Therefore nam7A
is a suppressor of tra l p A . As shown in Figure 16, CY5979 (nam7A/ada2A) grows at the
same rate as BY4282 (ada2A) on YPD plates containing 6 % ethanol and thus nam7A is
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Figure 14: mRNA Levels of TRA1 and ¡DH1. RNA was extracted from CY4434
(TRA1), CY5967 (tra lu ), CY5932 (nam7A), and CY5972 (tra liA nam7A ) strains. The
High Capacity cDNA RT Kit was used to obtain cDNA from the samples. A no RNA
control, and no reverse transcriptase controls were also used for each sample. Two-fold
serial dilutions o f 35 ng/pL o f cDNA from each sample were prepared and amplified by
PCR. PCR products were separated by electrophoresis on a 1 % agarose gel, and
visualized under UV light after staining with ethidium bromide. A) TRA1 cDNA levels
for all 4 samples, B) IDH1 cDNA levels for all 4 samples, and C) PCR water control
(H2O), no RNA control (-), a positive genomic DNA control (+), and no reverse
transcriptase controls for TRA1 (1), tralLA (2), nam7A (3), and tralLA nam7A (4).
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VPD

YPD + 6 % EtOH

YPD at 37 °C

TRA1/NAM7
t r a l^ l NAM 7

TRAl/nam 7A
t r a lfJn a m 7 A

Figure 15: Growth assays testing allele specificity of nam7A with tr a lFA. Growth of
CY4434 (THAI/ NAM7), CY4400 (tral fa/NAM7), CY5932 (TRAl/nam7A), and CY5974
(tralFAlnam7A) haploids were compared. Strains were grown in YPD media to stationary
phase, and 10-fold serial dilutions were plated onto rich media (YPD), YPD containing 6
% ethanol, or YPD grown at 37 °C. Plates were incubated at 30 °C unless otherwise
stated.
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A D A 2/N A M 7

a d o 2 A /N A M 7

AD A 2/nam 7A

a d o 2 A /n a m 7 A

Figure 16: Growth assays testing allele specificity of nam7A with ada2A. Growth of
CY4434 (ADA2/NAM7), BY4282 (ada2A/NAM7), CY5932 (.ADA2/nam7A), and CY5979
(ada2A/nam7A) haploids were compared. Strains were grown in YPD media to stationary
phase, and 10-fold serial dilutions were plated onto rich media (YPD), and YPD
containing 6 % ethanol. Plates were incubated at 30 °C unless otherwise stated.

not a suppressor of ada2A. Interestingly, CY5980 (nam7A/eaf3A) and CY5976
(nam7A/eaf7A) grow slower than BY7143 (eaf3A) and BY2940 (eaf7A) on YPD plates
containing 6 % ethanol grown at 35 °C indicating nam7A does not suppress eaf3A or
eaf7A, and in fact a synthetic slow growth is observed (Figure 17). Taken together, these
results suggest that nam7A is a specific suppressor o f Tral.
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Figure 17: Growth assays testing allele specificity of nam7A with eaf3A and eaf7A.
Growth o f CY4434 (.NAM7/EAF3/7), CY5967 (nam7AIEAF3/7), BY7143 (NAM7/eaf3A),
CY5980 (nam7A leaf3A), BY2940 (NAM7/eaf7A), and CY5976 (nam7A/eaf7A) haploids
were compared. Strains were grown in YPD media to stationary phase, and 10-fold serial
dilutions were plated onto rich media (YPD) grown at 30 °C, and YPD containing 6 %
ethanol grown at 35 °C.
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C h ap ter 4

1. R ationale
Tral and other members of the PIKK family of proteins contain two
conserved domains at the C-terminus, the PI3K and FATC domains. In other members of
the PIKK family, the PI3K domain is a kinase and the FATC domain regulates the kinase
activity of the adjacent PI3K domain. The PI3K and FATC domains of Tral/TRRAP do
not exhibit kinase activity, yet they are still important for Tral function. The FATC
domains o f mammalian ATM and DNA-PKcs interact with Tip60 in response to DNA
damage (reviewed in Lempiainen and Halazonetis. 2009). Furthermore, the recruitment
of yeast M ecl to DNA damage sites is dependent on the interaction of the FATC domain
of Mecl with Rfal (Nakada et al. 2005). Therefore, it is possible that the role of the Cterminal domains of Tral is to interact with other proteins, thus regulating one or more
activities o f Tral or the activity of the interacting protein. In order to identify
peptide/protein sequences with which Tral may interact, three experiments were
performed: gel filtration chromatography, over-expressing the C-terminus of T ral, and
phage display. M y aim was to identify w hether the P I3 K and FA TC dom ains o f Tral
in teract with other proteins.

Gel filtration chromatography was performed to determine whether the FATC and
PI3K domains of Tral stably associate with other proteins in vivo. Gel filtration separates
proteins on the basis of size, while maintaining the integrity of the protein complexes.
Therefore, if TralpoK/FATC interacts with other proteins in vivo, Tralpi3K/FATC expressed in
yeast may fractionate differently than T ra lPi3K/FATC expressed in E. coli. Gel filtration
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was a rapid method to explore whether further purification and mass spectrometry
experiments should be performed using TralpoK/FATCOver expression of the PI3K and FATC domains of Tral was performed to
determine whether the C-terminus o f Tral interacts with and sequesters the
transcriptional machinery. Over-expressing the strong transcriptional activator protein
VP 16 inhibits transcription in yeast because it sequesters the transcriptional machinery
from endogenous cellular activators (Berger et al. 1992). If the C-terminus of Tral was
toxic to the cell when over-expressed independently, it could be used as a tool to
genetically isolate interacting proteins; that is, suppressor mutations could be identified
that would provide clues into the identity o f the interacting molecules.
Phage display was performed to identify potential peptide sequences that could
interact with the PI3K and FATC domains of Tral (Tralpox/FATc)- One advantage to
using phage display is that a large number of potential peptide interactors can be
simultaneously screened. Peptides are displayed on the phage surface, and are easily
identified because their corresponding DNA sequences are encoded by the phage. These
peptide interactors could provide unique insights on the molecular interactions of
TralpoK/FATC- Furthermore, peptide inhibitors that destabilize Tral in vivo (similar to
tral la) could also arise, which would be useful in elucidating T ra l’s function.
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2. R esults
2.1 Gel Filtration Chromatography
One role for the PI3K and FATC domains of Tral could be to interact with other
proteins, thus regulating a function of Tral or a function of the interacting protein. As a
first step to analyze whether the C-terminal domains of Tral, the PI3K and FATC
domains, interact with other proteins, I expressed the C-terminal 458 amino acid residues
of Tral as a 9-Myc (Myc9) and 6-histidine (6HIS) fusion in yeast (Myc9-6FIISTralpoK/FATc)- If this protein interacts with other proteins it would fractionate with an
apparent size greater than its actual size when analyzed by gel filtration chromatography.
Sephadex® G-75 gel filtration beads, which exclude molecules larger than 70 kDa, were
used in a spin column for this experiment.
To determine the migration profile o f the C-terminus of Tral (residues 3290-3744)
when not in complex with other proteins, I expressed the C-terminal 454 amino acid
residues of Tral as a 6-histidine (6HIS) and general binding (GB) domain recombinant
protein (6HIS-GB-Tralpi3K/FATc) in E. coli (strain CE4048). This molecule does not
contain the Myc9tag but does contain the GB tag with a similar size (14 kDa). 6HIS-GBTralpoK/FATC expressed in E. coli primarily eluted from the G-75 centrifugation column
in the fraction following the first wash (Figure 18 lower panel). This agrees with the fact
that recombinant 6HIS-Tralpi3K/FATC is ~65 kDa (smaller than 70 kDa).
M yc9-6H IS-T ralPi3K/FATC was analyzed on the same column. As shown in Figure 18,

when residues 3286-3744 of Tral were expressed in yeast (on a multi-copy plasmid
under control of the MET3 promoter, strain CE5766) the protein was excluded from the
G-75 centrifugation column, eluting both in the flow-through and first wash fractions.
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Figure 18: Size exclusion chromatography of TralpuK/FATcexpressed in yeast and E.
coli. The C-terminus of Tral (Tral PI3 k/ f a t c ) was expressed both in E. coli CE4048

(6HIS-GB-Tralpi3K/FATC> residues 3290-3744) and in yeast CY5766 (Myc9-6HISTralpi3K/FATC, residues 3286-3744). Both constructs were ~65 kDa, expressing the Cterminus of Tral. Cell lysates from each were analyzed on G-75 Sephadex spin columns.
0.5 mg of protein was loaded onto each column in a total volume of 100 pL of PO4
Buffer 150. Columns were washed three-times (W1-W3) with 300 pL PO4 Buffer 150.
Twenty microlitres o f each fraction was loaded onto two 10 % SDS-PAGE gels,
transferred to PVDF membranes, and probed with the indicated antibodies. Band
densities were quantified using the SpotDenso program of Alphalmager 3400. The
histogram shows the band intensity o f protein found in FT, W l, W2, and W3 for each
sample as a percentage of that found in the lysate.
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This suggests that Myc9-6HIS-Tralpi3K/FATC is likely interacting with one or more
proteins in yeast. An obvious caveat of this experiment is that the two forms of the
protein, though o f very similar size (~14 kDa), are not identical. I can thus not exclude
the possibility that the differences in migration are due to the different tags.

2.2 O ver-expressing Myc9-6HIS-Tralpi3K/FATc
Overexpression of transcriptional activators in yeast can result in toxicity, likely
due to their sequestration of essential transcription factors. If toxicity is observed, it
provides an excellent screening tool to genetically identify the interacting partners. The
C-terminus of Tral (PI3K and FATC domains) was over-expressed to determine whether
it was toxic to the cell. The yeast strain CY4455 contains a plasmid expressing residues
3286-3744 containing the PI3K and FATC domains of T ral (Mycg-TralpoK/FATc) under
control of the MET3 promoter. Yeast strain CY2286 was also similarly constructed as a
control, and contains a plasmid expressing Nggl (Mycg-Nggl). The MET3 promoter is
repressed in a dose-dependent manner by methionine (Mao et al. 2002). I thus analyzed
whether over-expression of Myc9-Tralpi3K/FATC affected growth of cells by growing cells
in the absence o f methionine. Serial dilutions of cells expressing either MycgTralpBK/FATC or the Mycg-Nggl control were plated onto minimal plates containing 0
pM, 5 pM, 10 pM, or 20 pM of methionine. As shown in Figure 19A, the cells grew
comparably at every concentration o f methionine, indicating that Mycg-TralpBK/FATC, at
levels that could be obtained from the MET3 promoter, is not toxic to cells.
To verify that the Mycg-TralpBK/FATC was expressed, yeast strains CY4486 (MycgN g g l) and CY4455 (Mycg-TralpBK/FATc) were grown in minimal media lacking
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Figure 19: Over expression of the C-terminus of T ral. A) Growth of strains
containing plasmids expressing Mycg-Nggl (Control) or the C-terminus of Tral from
residue 3286 to 3744 (Mycg-TralpoK/FATc) under the MET3 promoter were compared on
minimal plates containing the indicated concentrations of methionine. The level of
expression decreases with increasing methionine (Mao, 2002). B) Mycg-Nggl (Control)
and Mycg-TralpBK/FATC (Tral) were separated by SDS-PAGE on a 10 % gel, transferred
to a PVDF membrane, western blotted, and probed with a primary a-myc antibody.
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methionine or containing 20 pM methionine. Yeast extracts were prepared and protein
extracts of cells with the Mycg-TralpoK/FATC or Myc9-Nggl plasmids were separated by
SDS-PAGE, transferred to PVDF membranes and Western blotted (Figure 19B). Both the
Myc9-Nggl control and Myc9-Tralpi3KyFATC proteins were expressed in the absence of
methionine.

2.3 Phage Display
Phage display was performed to determine whether peptide sequences could be
identified that interact with the PI3K and FATC domains of Tral (TralpoK/FATc)- If a
peptide that specifically interacts with the Tral C-terminus was discovered, it may
provide clues as to which proteins interact with TralpoK/FATC- In addition these peptides
could serve as inhibitors of Tral function.
The C-terminus of Tral (residues 3286-3744) was expressed as a recombinant
protein (6HlS-GB-Tralpl3K/FATc) in E. coli (strain CE4048). A control recombinant
protein (6HIS-GB) was also expressed in E. coli (strain CE4336). The PhDIM-12
dodecapeptide M13 phage library (NEB), which covers 10y independent linear clones,
was used in this experiment. The phage library was first incubated with 6HIS-GB control,
to remove any phage that may bind to the IgG Sepharose or affinity tag. The phage were
then bound to and eluted from the 6HIS-GB-TralPBK/FATC column. Following
amplification of phage, 5 rounds of panning were performed. Approximately ten-fold
phage enrichment was observed after five rounds of panning, a result suggesting that
specific phage had not been enriched. Normally, phage would be enriched by at least
1000 fold following only 3 rounds of panning (Duncan et al. 2011). In the final round, 5
plaques were sequenced and 4 of them contained the same sequence. When this peptide
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was tested for specificity of 6HIS-GB-TralPi3K/FATC, it bound equally to extracts from
both the control 6HIS-GB and 6HIS-GB-TralPi3KyFATC (results not shown), strongly
suggesting that it was not specific to 6HIS-GB-TralPi3K/FATCTo rule out trivial explanations for not isolating a specific interacting peptide, I examined
whether phage was exposed to the target protein. The proteins used in the experiments
(6HIS-GB and 6HIS-GB-TralPi3K/FATc) were eluted from the IgG beads after each round
o f the experiment to ensure that protein was indeed present throughout the experiment
(Figure 20). Protein bands corresponding to 20 kDa for 6HIS-GB and 65 kDa for 6HISG B-TralPi3K/FATC were observed in the elutions (Figure 20). Therefore, phage was
exposed to target protein. Since one peptide bound to both 6FIIS-GB and 6HIS-GBT ralPi3K/FATC, it likely recognizes glycoprotein B since this domain was present in both.
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Figure 20: Proteins used for Phage display experiments. Crude extracts from E. coli
containing plasmids expressing recombinant proteins of A) 6HIS-GB and B) 6HIS-GBTralpBK/FATc, were applied to IgG sepharose beads. Proteins were eluted from the IgG
beads with IX Laemmli buffer (63 mM Tris HC1, 10 % Glycerol, 2 % SDS, 0.0025 %
Bromophenol Blue, pH 6.8) and heating at 65 °C. Proteins were separated by SDS-PAGE
on 15 % and 10 % gels respectively. Proteins were transferred to PVDF membranes, and
western blotted probed with a 5HIS antibody to ensure that recombinant proteins 6HISGB and 6HIS-GB-Tralpi3K/FATC, were present throughout the phage display experiment.
Lysates (lane 1), unbound protein (lane 2), washes (lanes 3-6) and eluted proteins (lane 7
- 6HIS-GB and 6HIS-GB-Tralpi3K/FATc) arc shown.

72

C h ap ter 5: D isc u ssio n
1. P r e lu d e
This discussion will begin with an overview of characterizing suppressor
mutations using next-generation sequencing. 1 will then propose several models for how
nam7A may be suppressing tra l la- Differences in growth and suppression caused by
variations in strain backgrounds will be discussed. I will discuss a possible model of how
tti2ps may be suppressing tral fa, and how the FATC domain of Tral may be involved in
protein interactions. Possible future directions that are currently being pursued will be
encompassed throughout this discussion.

2. Id e n tify in g s u p p r e s s o r m u ta tio n s u sin g w h o le g e n o m e
s e q u e n c in g

Identifying genetic interactions is a powerful approach to provide insight into
protein function. Particularly powerful is the approach of suppressor genetics which can
reveal gene function, protein interactions, or parallel pathways in which the gene product
is involved. In the suppressor genetics approach, the cell compensates for the cellular
changes resulting from one genetic change by making a second suppressor mutation. The
approach is particularly powerful because it requires no assumptions regarding the gene’s
function, and since the cell does the work it is not influenced by experimental bias. There
are many examples in the literature that document the utility of suppressor genetics. For
example, the SPT genes were originally identified by Fred Winston’s laboratory as
suppressors of the transcriptional inhibitory effects caused by Ty transposable elements
(Winston et al. 1984). This suppression provided clues that Spt proteins had a role in
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transcription. The ADA genes were first identified in the Guarente laboratory as
suppressors o f the toxicity of overexpression of the strong transcriptional activator VP 16
(Berger et al. 1992). This suppression provided clues into the role of the Ada proteins in
regulating transcription.
The initial identification of suppressor mutations through screens is relatively easy
because the cells do the work. I performed a suppressor analysis using the tr a lu FATC
domain mutant as the primary mutation. The CY4018 (itra it 4) strain grows slowly on
YPD plates containing 4 % ethanol. Therefore, to screen for suppressor mutations of
tralLA, I plated the CY4018 strain on YPD plates containing 4 % ethanol and selected for
colonies that were growing quickly. Eleven extragenic suppressor mutations were
identified using this method. Random spore analysis was performed by mating
suppressors with CY5522 (tral la, MATa) and testing whether spore colonies grew
quickly or were sensitive on YPD plates containing 4 % ethanol or grown at 37 °C. A 2:2
(slow growth on ethanol : fast growth on ethanol) segregation of spores indicates that the
suppressor mutation is linked to a single gene. For es2, 27 spore colonies were analyzed;
13 grew quickly on YPD plates containing 4 % ethanol and 14 grew slowly, indicating a
2:2 segregation. Cumulatively, in the es38 and es41 complementation group, 42 spore
colonies were analyzed; 19 grew quickly on YPD plates containing 4 % ethanol and 23
grew slowly, indicating an approximate 2:2 segregation. Had the complementation group
been linked to more than one gene, 25% (~10 colonies out o f 42) would have been
expected to grow quickly on YPD plates containing 4 % ethanol. The next step in
characterizing suppressor mutations involves determining whether the genes are
dominant or recessive, and the number o f complementation groups. Since yeast stably
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exists as both haploid and diploid, determining complementation groups is straight
forward. Through classical genetic approaches, I characterized the 11 tralLA suppressor
mutations as recessive and belonging to three complementation groups.
Until recently, the difficulty with suppressor genetics has come in the
identification of the suppressor mutations. Methods for identifying the mutations have
involved the addition of gene pools to revert the suppressed phenotype, or revert a novel
phenotype (if it exists) caused by the suppressor. There are numerous difficulties with
these traditional methods. For example, good gene pools are required, the plasmid may
not fully revert the phenotype, and even after having isolated a reverting plasmid, the
gene must be located. These traditional methods can be labour intensive and time
consuming (Hobert. 2010). The low costs of whole-genome sequencing have overcome
many o f the difficulties in identifying the suppressor mutation.
Next generation sequencing is changing the landscape of genetics approaches
because it allows for whole genome sequencing to be used to identify mutations (Hobert.
2010). Next-generation sequencing is a rapid and cost-effective approach to identifying
mutations (Smith et al. 2008). Various laboratories have successfully used whole genome
sequencing to identify mutations, and many more studies are underway (reviewed in
Hobert. 2010).
The ABI (Applied Biosystems) SOLiD (Sequencing by Oligonucleotide Ligation
Detection) 4.0 next-generation sequencing platform was used in our studies. ABI SOLiD
is a next-generation sequencing approach that sequences using oligonucleotide ligation
with dinucleotide probes. The DNA is fragmented and a library created. Single-stranded
DNA fragments are attached to the surface of beads using adaptors. Each adaptor has a
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unique barcode so that each sequence read contains a barcode. For paired-end reads, the
library of DNA fragments is prepared and both ends of the fragments are sequenced with
corresponding barcodes. Fluorescently labeled oligonucleotides are added, each specific
for the identity o f the two bases. These dinucleotides compete for incorporation into the
DNA templates and the fluorescent signal is measured. Using this 2-base encoding
approach, every single position or base in the DNA template is queried twice, thereby
yielding a low base calling error (Chee-Seng et al. 2010). ABI SOLiD 4.0 has the lowest
error rate (as of 2010) compared to the other next-generation sequencing platforms
(Chee-Seng et al. 2010).
For my suppressor genetic analysis, I used a sequence alignment program,
Bowtie, to map reads from each sample to the SGD reference genome. The SGD
reference genome was used because it could easily be downloaded and converted to
colourspace, therefore allowing mapping of the ABI SOLiD colourspace reads. The “v 3” parameter was used for Bowtie, which allows reads containing a maximum of three
mismatches to be aligned to the SGD reference genome. This “v -3” parameter has been
used in other studies that successfully identified point mutations (Smith et al. 2008). 1
also mapped paired-ends separately, rather than mapping them together as paired-ends. 1
did this so that reads without a paired-end were not eliminated from the analysis. In this
manner, a higher percentage o f total reads mapped to the genome, thereby maximizing
the genome coverage.
An initial list of polymorphisms was obtained by eliminating those
polymorphisms with a Phred score below 20. This means that polymorphisms present
less than 99 % of the time were eliminated from the analysis. The tral fa suppressor
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mutations were originally identified in the consortium background (BY4741). The
sequence of this strain background closely matches what is found in the SGD reference
genome, so the initial list of filtered polymorphisms was short (there were -100). Since
the tralpA pre-mutagenesis control was sequenced along with two tralFA samples
containing the same suppressor mutation, the background polymorphisms found in the
tra lFA control were easily subtracted. Additionally, any polymorphisms that were not
found in both of the suppressor mutation samples were eliminated. Once synonymous
substitutions were eliminated, there was only one candidate suppressor for tra lFA. This
suppressor was a phenylalanine (F) to serine (S) mutation at amino acid residue 328
(tti2fs). Therefore whole-genome sequencing combined with Bioinformatic analysis
easily identified this suppressor.
The same approach and reasoning described above for the tra lfA mutation was
used to identify the tra lLA suppressor mutations. However, the tra lLA suppressor
mutations were identified in a different strain background (KY320) than tra lFA. The
sequence of this strain background does not so closely match what is found in the SGD
reference strain. Therefore, the original list of polymorphisms was long (there were
>3000), making the analysis more challenging. The background polymorphisms found in
the tral la control sample were subtracted from each suppressor strain. Since tra lLA
extragenic suppressor mutation es2 was in a separate complementation group than es38
and es41, those polymorphisms found in all three of these samples were also eliminated
from the analysis (narrowing the polymorphism list down to <500). Synonymous
substitutions were eliminated as before. Mutations in non-functional transposable
elements, and highly repetitive intergenic regions were also eliminated. Once all these
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background polymorphisms were eliminated, there was only one candidate suppressor for
es2. This suppressor was a tryptophan (W) to opal mutation at amino acid 165 in NAM7
(nam?W-uM)■
There was only one candidate suppressor for the es38 and es41 complementation
group, a mutation in srb6. However, there was no coverage of this mutation in the tra lLA
reference sample. After sequencing the SRB6 gene, I found that it was in fact a
background mutation also present in tra lLA. There were no other candidate suppressors
remaining for the es38 and es41 complementation group. There were no mutations
present in RNA surveillance components Upf3 and Nmd2 in the es38 and es41
complementation group. Therefore, the identity of these suppressor mutations remains
unknown. Given there was low coverage in some areas of the genome, it is possible that
the suppressor mutation lies in an area o f low coverage. A study sequencing the Pichia
pastoris (methylotrophic yeast) genome using ABI SOLiD also found that some regions
o f the genome had more coverage than others (Smith et al. 2008). Since the “v -3”
parameter in Bowtie was used, one limitation is that if the mutation were in a region with
more than 3 polymorphisms nearby, the sequence would not have mapped to the SGD
genome. However, 3 polymorphisms was the maximum number of mutations allowed
using the Bowtie program so I could not increase this parameter. It may have been useful
to build a reference genome using the tra lLA control, rather than using the SGD reference
genome. However, it would have been extremely difficult to do this (Dr. Greg Gloor,
personal communications) especially for a beginner Bioinformatician. Therefore, a future
direction would be for someone with advanced knowledge in Bioinformatics to build a
reference genome out o f the tralLA sequences. In this manner, the initial list of
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polymorphisms would be low, heightening the chances of identifying the mutation of
interest. Another reason why es38 and es41 may not have been identified is there was no
method available using Bowtie to test whether the suppressor was an insertion or
deletion. Dr. Gloor is looking into new programs, such as VarScan, that can identify
insertions and deletions (Dr. Greg Gloor, personal communications).
ABI SOLiD 4.0 sequencing platform and my Bioinformatic analysis successfully
identified tti2Fs and nam7w.UMas the suppressor mutations of tra lFA and tra lLA
respectively. Therefore, I have demonstrated that this method is a rapid and effective
approach to identifying suppressor mutations.

3. It is u n lik e ly th a t n a m 7 A is in c r e a sin g TRA1 mRNA

One simple explanation for nam7A suppression of tr a lu is that nam7A is not
targeting mRNAs for degradation and this is causing an increased stability of TRA1
mRNA in the cell. mRNAs containing premature stop codons in ACT1, PGK1, STE3, and
MATa were stabilized in nam7A strains (Leeds et al. 1991). Since the tr a lu and tra lFA
mutants do not contain premature stop codons and the mutations are located very close to
the C-terminus (ie: not upstream of DSE), this model seems unlikely. However, the NMD
surveillance complex also targets regular mRNAs (Gardner. 2010) and mRNAs
containing programmed frameshift mutations for NMD (Bidou et al. 2000). Hence, I
cannot exclude the possibility that TRA1 mRNA is a target of this pathway. My
preliminary experiments suggest that there are no changes in TRA1 mRNA levels
between TRA1, tr a lu , nam7A and a double tralLA nam7A. This would suggest that
suppression by nam7A is not by increasing TRA1 mRNA levels. To obtain a more
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definitive result, performing this experiment using real time PCR to observe a linear
range and quantitatively confirm that there are no changes in TRA1 RNA levels should be
done.

4. P o s s ib le m e c h a n ism s for su p p r e s s io n o f t r a h A by n a m 7 A
4.1 RNA’s norm ally degraded by NMD may be com pensating for lack of
transcription due to tralLA

Changes in gene expression can occur in response to environmental stress.
Phenotypes displayed by tral la may occur because Tral is unable to regulate
transcription of genes required in times o f environmental stress (Hoke et al. 2010).
Suppressor mutations may act by compensating for this change in gene expression. An
example of such a model comes from the analysis of suppressor mutations of the deletion
o f the SAGA component spt20, which results in changes in histone acetylation and gene
expression. The null version of the histone de-acetylase (HDAC) gene hdal is a
suppressor o f spt20A (Larschan and Winston. 2005). By deleting the HDAC h d a l, the
lack of HAT activity is compensated for and transcription is restored, at least at certain
genes.
Gene expression is not only controlled by regulating transcription, but also
through degradation of RNA transcripts. In fact, the RNA surveillance complex
consisting of Nam7, UpO, and Nmd2, regulates 5’decapping of both regular and
nonsense mRNAs (Gardner. 2010, He and Jacobson. 2001). In this manner, Nam7 may
regulate gene expression through RNA degradation (Gardner. 2010). Therefore, one
model is that while tral la is unable to regulate transcriptional activation of certain genes
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required for the cellular stress response, nam7A (or upfSA or nmd2A) compensates at the
RNA level by knocking out the NMD process and increasing the life of certain RNA
transcripts (Figure 21).
The compensatory model would agree with nam7A partially restoring some of the
growth phenotypes displayed by tr a lu because only processes that require genes
regulated by NMD would be affected. To further test this model, expression profiling
should be performed in a nam7A tr a lu background. These data could be compared to the
expression profiling data that are already available for tr a lu (Hoke et al. 2010), to
determine whether nam7A equilibrates RNAs with altered expression caused by tra lLA.

4.2 T r a l m ay be directly involved in NMD through regulating Nam7
Deletion of any of the three components of the NMD surveillance system (nam7,
nmd2, and upf3) leads to nonsense-suppression phenotypes (Gonzalez et al. 2001). Since
the nam7w-uM suppressor mutation was recessive, this suppressor is likely acting as a loss
of function mutation. Indeed, 1 found that nam7A, nmd2A, and upf3A are suppressors of
the slow growth on ethanol phenotype displayed by tr a lu suggesting that it is loss of the
NMD machinery that suppresses tr a l u ■nam7A also suppressed Tral FATC domain
mutant tr a lu , but not SAGA or NuA4 components ada2A, eaf3A or eaf7A. Since nam7A
suppresses Tral FATC domain mutants, this could indicate a role for Nam7 in regulating,
or being regulated by, the FATC domain of Tral.
In higher eukaryotes such as C. elegans and humans, SMG2, SMG3, and SMG4
are homologs of Nam7, Nmd2 and Upf3 respectively (Gonzalez et al. 2001). In these
higher eukaryotes, SMG2 must be phosphorylated in order for NMD to take place
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Figure 21: A model explaining compensatory suppression of tr a lLA by nam 7A. In
times o f stress, Tral regulates transcription of stress-response genes and Nam7 controls
expression at the RNA level by degrading RNA transcripts. When tral la mutation
occurs, certain stress-response genes are transcribed at a lower level, however, Nam7
degrades the RNA transcripts as normal. When nam7A occurs in the context of tral la,
these transcripts do not get degraded and the appropriate proteins can be translated in
response to stress. This model would apply only to genes regulated both by Tral and
Nam7.
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(Wilusz et al. 2001). The PIKK protein SMG1, and two other proteins SMG3 and SMG4
are all required for the phosphorylation o f SMG2 (Wilusz et al. 2001). Since SMG1 is a
kinase and phosphorylates Nam7 in vitro, it is likely directly responsible for
phosphorylating SMG2 (Grimson et al. 2004). Intriguingly, there is no yeast homolog of
SMG1. Furthermore, Nam7 is not phosphorylated in yeast. Therefore, regulation of
Nam7 activity must be different between yeast and higher eukaryotes (Wilusz et al.
2001). However, SMG1 is related to Tral in that it is part of the PIKK family. Therefore,
it is possible Tral is working by a different mechanism than SMG1 to regulate Nam7.
Although the C-terminus of Tral lacks kinase activity, it could still be regulating Nam7,
either directly or through another protein.
Figure 22 shows a tentative model for regulation of Nam7 by T ra l. Perhaps
the FATC domain is normally required for repressing activity of Nam7. When tral la
occurs, the FATC domain of Tral is unable to repress Nam7. Unregulated Nam7 could
then result in excessive degradation of mRNAs, consequently lowering protein levels and
causing some of the stress-related phenotypes observed in tral la and tra lfA. By deleting
a component of the NMD machinery (such as upf3A, nmd2A or nam7A), NMD would be
eliminated and some o f the tral la phenotypes reversed. Further experiments are being
performed to test whether Tral has a direct role in NMD. A HIS4-LacZ fusion of PGK1
containing a premature stop codon upstream of the DSE, is currently being constructed in
the Brandi laboratory. If Tral is directly involved in NMD, tral la should show increased
read-through of the nonsense codon.

5. D iffe r e n c e s in str a in b a c k g r o u n d s c a u se g ro w th d iffe r e n c e s
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Figure 22: A model for Nam7 regulation by T ral. In higher eukaryotes, SMG1 (along
with SMG3 and SMG4) is required for phosphorylation of SMG2 (a Nam7 homolog).
Phosphorylation (P) of SMG2 is essential for nonsense-mediated mRNA decay (NMD) to
take place. There is no yeast homolog o f SM G1 and Nam7 is not phosphorylated in yeast.
Since Tral is structurally related to SMG1,1 propose that Tral is repressing (R) Nam7
activity, thereby regulating NMD. In the mutant tral la, perhaps this results in excessive
NMD causing too much RNA degradation. When Nam7 is deleted (nam7A), the loss of
NMD may restore balance to this pathway.
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In the KY320 strain background (in which tralLA is on a CEN plasmid), P H 05
expression is reduced in the CY4018 (itral la) strain, and partially restored in the strains
containing suppressor mutations. However, in the BY4741 consortium background (in
which tral la is integrated into the genome), nam7A does not restore PH 05 expression
(Dr. Chris Brandi, personal communication - results not shown). Furthermore, nam7W-uM
in the KY320 strain partially restores the slow growth phenotype at 37 °C caused by

tral la, whereas nam7A in the consortium background does not. These differences in
suppression may occur because nam7W-uM causes an increase in plasmid copy number
thus increasing the level of tral la in the KY320 background. Therefore, experiments are
currently being repeated using nam7A in the BY4741 background to determine which
phenotypes displayed by tralLA are suppressed by nam7A, and which phenotypes are due
to strain background differences.

6. n a m 7 A m a y b e h e lp in g to s ta b iliz e tralLA in th e c o n te x t o f SAGA
In addition to nam7A, all 3 complementation groups of extragenic suppressor
mutations partially restored growth of strains containing tralLA on ethanol, tunicamycin,
and tert-butylhydroperoxide, which are characteristic of SAGA mutants. Extragenic
suppressor mutations did not restore growth phenotypes displayed by tralLA on benomyl,
rapamycin, or geneticin (results not shown), which are characteristic of NuA4 mutants.
Therefore, perhaps the tralLA extragenic suppressor mutations are suppressing T ra l’s role
within SAGA, more so than in NuA4. A high throughput screen identified the SAGA
component Sgf29 as interacting with Nam7 (Gavin et al. 2006). Therefore, Sgf29 could
be involved in linking Tral to a role in NMD in the context of SAGA.
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7. T h e PI3K a n d FATC d o m a in s o f T r a l m a y b e in v o lv e d in p r o te in p r o te in in te r a c tio n s

One proposed model for FATC domain function is that it may be required for
protein interactions to take place. The hydrophobic residues found within the FATC
domain of Tral resemble those residues found in proteins that interact with PDZ domains
(Tonikian et al. 2008). Therefore, perhaps the FATC domain is required for protein
interactions of T ral. The FATC domain in other members of the PIKK family is required
for kinase activity of the PI3K domain. Although Tral does not possess kinase activity, it
may still play a regulatory role by promoting protein interactions at the C-terminus.
Gel filtration chromatography was performed to determine whether the PI3K and
FATC domains o f Tral interact with other proteins. The PI3K and FATC domains of
Tral were expressed both in yeast (Myc9-6HIS-Tralpi3K/FATc) and in E. coli (6HIS-GBTralpBK/FATc)- The GB domain is approximately the same size as the Myc9 tag (14 kDa),
and therefore both constructs were ~65 kDa. When expressed in yeast, Myc9-6HISTralpoK/FATC was excluded from the G-75 spin column, eluting primarily in the void and
after the first wash. When expressed in E. coli, 6HIS-GB-TralPi3K/FATC eluted primarily
after the first wash. This result suggests that the C-terminus o f Tral may be interacting
with a protein or protein complex. One limitation of this approach was that the tags on
the two proteins, although the same size, were not identical. Hence, it is possible that
differences in elution could be due to the different tags.
In light of the possibility that the C-terminal domain of Tral may be interacting
with other proteins, experiments were performed that would allow for their identification.
The PI3K and FATC domains of Tral were over-expressed to test whether this would be
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toxic to the cell. If the C-terminus of Tral was toxic to the cell when over-expressed
independently, it could be used as a tool to genetically isolate interacting proteins. Over
expressing the C-terminus of Tral was not toxic to the cell, and therefore this is not a
possible manner to identify Tral FATC interacting proteins.
Phage display was also performed to identify potential peptide interactors. Phage
display using Tral and related proteins has been successfully performed by other
laboratories. One study identified novel interactions of HMG-1 using the PhD-12 phage
display library (Dintilhac and Bemues. 2002). Another study used Tral as a target for
identifying transcription factors with the potential as therapeutics for transcription related
ailments (Majmudar et al. 2009). This study looked for peptide interactors of Tral
(residues 3092-3524) using phage display and the same PhD-12 library. They identified
one peptide that was able to bind to that region of T ral, and to a Mediator component
Med 15 (Majmudar et al. 2009). I was exploring residues 3286-3744 of Tral.
Unfortunately, no peptide interactors specific to this region o f Tral were identified.
Reasons may include: lack of complexity in the phage library, simple peptides may not
adopt a conformation able to bind the FATC domain, or the FATC domain may only
interact with other molecules in the context of the intact Tral protein.
Suppression of tra lFA by tti2Fs could arise by the direct interaction of these proteins
as they are known to co-exist in the ASTRA complex (Shevchenko et al. 2008). Tti2
directly interacts with Tel2, a coordinator o f PIKK activity (Takai et al. 2007) and
another member of ASTRA. As an initial test to determine whether Tral and Tti2 were
directly interacting, I constructed a fusion protein of Tti2 (residues 165-420) with a GST
tag and expressed this construct in E. coli. Tti2 was immobilized onto a glutathione resin,
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and CE4048 (C-terminus of T ral, residues 3286-3744 in E. coli) was incubated with the
resin to determine whether the recombinant proteins would interact. However, these
regions o f Tral and Tti2 did not interact (results not shown). The interaction between
Tral and Tti2 in yeast is currently being investigated in the Brandi laboratory. So far,
immunoprécipitations have not demonstrated a strong interaction between wild-type Tral
and Tti2; however, tra lFA interacted weakly with Tti2. Therefore, perhaps tra lFA is not
able to release Tti2, and the tti2Fs mutation will reverse this effect. These models are
preliminary and are currently being investigated further.
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C hap ter 6: C o n clu sio n s
Suppressor genetics is a powerful method for identifying new interactions or
protein regulatory functions. My research identified nam7w_uM as a suppressor of traliA- I
demonstrated that deletions of nam7, nmd2, and upf3 are suppressors of Tral FATC
domain mutants tra lLA and tral fa- My bioinformatics analysis also identified the uU fs
suppressor of tral fa- Allele specificity tests showed that these suppressors do not
suppress other SAGA or NuA4 mutants, suggesting that they specifically target Tral
function.
Nam7 is part of the surveillance complex mediating NMD. In higher eukaryotes,
the PUCK protein SMG1 is required for the phosphorylation of SMG2 (Nam7 homolog).
Phosphorylation o f SMG2 is required for NMD to occur. Since Tral is structurally
related to SMG1, perhaps it is also regulating Nam7 in the NMD pathway. Alternatively,
lack of NMD may be compensating for transcriptional defects caused by tra lLA by not
degrading RNA transcripts. Further experiments are currently underway to test whether
Tral has a direct role in NMD.
Tral is a member of three major protein complexes: SAGA, NuA4, and ASTRA.
It is a member of the PIKK family o f proteins which are important cellular regulators.
Although the function of the FATC domain of Tral is unknown, it may be required for
protein interactions to take place. My gel filtration results suggest that Tral is interacting
with other molecules within the cell. The results of this thesis have linked Tral to a new
cellular process - NMD, and further connected Tral to the ASTRA complex.
Deciphering the FATC domain function o f Tral may be a key in connecting Tral with
new regulatory processes.
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A p p en d ix :
Table SI: Yeast and E .coli strains
Description
Strain
Number
KY320
CY2706

Plasmids

Chen, 1988

M A T a u ra 3 -5 2 a d e 2 -1 0 1 tr p l - A l
lys2 -8 0 1 h is3 -A 2 0 0 leu 2\:P E T 5 6

Isogenic to KY320 except

Reference

Y C p la c 2 2 -m y c 9- TRA1

Hoke, 2010

Y C p la c2 2 u -m yc9-tra 1-L3 733A

Hoke, 2010
Hoke, 2010
This study
This study
This study

tr a lv J n lO L U K

CY4018
CY3003
CY4413
CY5522
CY5579
CY5580
CY5581
CY5582
CY5583
CY5584
CY5585
CY5586
CY5587
CY5588
CY5750
CY5666
CY5758
CY5603
CY5688
CY5690
CY5691
CE4336
CE4048
ER2738
BY4741
BY4742

Isogenic to CY2706
Isogenic to CY2706
Isogenic to KY320
Isogenic to CY3003 except M ATa
e s2 (n a m 7 w-um), otherwise isogenic
to CY4018
e s l 2 , otherwise isogenic to CY4018
e s 3 5 , otherwise isogenic to CY4018
e s3 6 , otherwise isogenic to CY4018
e s3 7 , otherwise isogenic to CY4018
e s 3 8 , otherwise isogenic to CY4018
e s3 9 , otherwise isogenic to CY4018
e s 4 0 , otherwise isogenic to CY4018
e s 4 1 , otherwise isogenic to CY4018
e s 4 2 , otherwise isogenic to CY4018
e s4 3 , otherwise isogenic to CY4018
Isogenic to CY5579 except M ATa
Isogenic to CY5584 except M A Ta
Isogenic to CY5587 except M ATa
Isogenic to CY5579
Isogenic to CY5584
Isogenic to CY5587
ER2566 (NEB strain)
ER2566 (NEB strain)

Y C p la c2 2 -m y c 9-TRA 1
Y C p la c 2 2 -m y c 9- TRA 1
Y C p la c 2 2 u -m y c 9-tra l-L 3 7 3 3 A
Y C p la c 2 2 u -m y c 9- tr a l -L 3 733A
Y C p la c2 2 u -m yc9-tr a l- L 3 733A
Y C p la c 2 2 u -m y c 9- tr a l -L 3 733A
Y C p la c2 2 u -m y c 9-tra 1-L3 733A
Y C p la c 2 2 u -m y c 9-tr a l- L 3 733A
Y C p la c2 2 u -m yc9- tr a l- L 3 733A
Y C p la c2 2 u -m yc9-tr a l- L 3 733A
Y C p la c2 2 u -m y c 9-tra 1-L 3 733A
Y C p la c 2 2 u -m y c 9-tr a l- L 3 733A
Y C p la c 2 2 u -m y c 9-tra l-L 3 7 3 3 A
Y C p la c2 2 -m y c 9-tra 1-L 3 733A
Y C plac2 2 -m y c 9-tra 1-L 3 733A
Y C p la c 2 2 -m y c 9-tra l-L 3 7 3 3 A
Y C p la c 2 2 -m y c 9-TRA 1
Y C p la c 2 2 -m y c 9-TRA 1
Y C p la c 2 2 -m y c 9-TRA 1

6HIS-GB-pET21a
6HIS-GB-Tral pi3k/fatc~pET2 1 a

M A T a h is3 A l leu 2 A 0 m et 15AO
u ra3A 0
M A T a h is 3 A l leu 2 A 0 Iys2A 0 u ra 3 A 0

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
NEB strain
Winzeler,
1997
Winzeler,
1997
Winzeler,
1997

BY 4743

M A T a/a h is 3 A l/h is 3 A l le u 2AO
7leu2A0 lys2A 0/L Y S 2
M E T 15 /m e tl5 A 0 u ra3A 0 7ura3A 0

CY4486
CY4455
CY5766
BY46214

Isogenic to BY4742
Isogenic to BY4742
Isogenic to BY4742

CY5932

M A Ta h is3 A l leu 2 A 0 m et 15AO
u ra 3 A 0 n am 7A \\kan R

This study

CY5933
CY5938

Isogenic to CY5932 except M ATa

This study
This study

M A T a/a h is 3 A l/h is 3 A l leu 2A 0
lys2A 0/L Y S 2 M E T 1 5 /m e tl5 A 0
u ra3A 0/u ra3A 0 + c a n lA : :L E U 2 + MFA lp r -H ! S 3 /C A N l + nam 7A :±<m R

M A Ta h is3 A l leu 2 A 0 m et 15AO
u ra 3 A 0 nam 7A ::nalR

pS14 (Myc9-Nggl)
pS 17 (Myc9-T ra 1 p b k /f a t c )
pS26 (Myc9-6HIS-TralPi3K/FATc)

This study
This study
This study
Tong et al.,
2001
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CY5939
BY41905

CY5934
CY5935
BY44702

This study
Tong et al.,
1997

Isogenic to CY5938 except M A T a
M ATdJa h is 3 A l/h is 3 A l leu 2A 0
lys2A 0/L Y S 2 M E T I5 /m e tl5 A 0
u ra 3 A 0 /u ra 3 A 0 + c a n lA ::L E U 2 + M FA lp r -H I S 3 /C A N l + n m d 2 A :± a n
M A T a h is 3 A l leu 2A 0 m et 15AO
u ra 3 A 0 n m d2A :\kanR

This study

Isogenic to CY5934 except M A T a

This study
Tong et al,
1997

M A T a/a h is 3 A l/h is 3 A l leu 2A 0
lys2 A 0 /L Y S 2 M E T I 5 /m e tl 5AO
u ra 3 A 0 /u ra 3 A 0 + c a n lA ::L E U 2 + MFA 1p r-H IS 3/C A N I + u p ftA :: kan*

CY5936

M A T a H1S3 leu 2A 0 m et 15AO u ra 3 A 0
upf3 A :\kanR

This study

CY5937

Isogenic to CY5936 except M A T a
and h is3A

This study

CY5974

M A T a u ra3A 0 L E U 2 m et 15AO t r a lF 3 7 4 4 A -H IS3 nam 7A ::kan*

CY5976

M A T a h is3 A l leu 2A 0 m et 15AO
u ra 3 A 0 e a fiv . kan* nam 7A ::na\R
M A T a h is3 A l leu 2A 0 m et 15AO
u ra 3 A 0 a d a 2 :\ kan* n am 7A \\ nat*

This study

CY5980

M A T a h is3 A l leu 2A 0 m et 15AO
a ra 3 AO e a f3 \: kan* n a m 7A:: nat*

This study

CY5983

M A T a u ra 3 A 0 leu 2A 0 m e t 15AO t r a l L 3 7 3 3 A -H IS 3 upf3A:: kan*

Y H R 100C

in Y cp la c3 3

This study

CY5972

M A T a u ra 3 A 0 leu 2A 0 m e tl5 A 0 t r a l L 37 3 3 A -H IS 3 nam 7A ::kanR

YH R 100C

in Yep la c 3 3

This study

CY5996

M A T a u ra 3 A 0 leu 2A 0 m et 15AO t r a l L 37 3 3 A -H IS 3 nm d2A :: kan"
M A T a u ra 3 A 0 h is3A 0 leu 2A 0 TRA1H IS3

Y H R 100C

in Y cp la c3 3

This study

Y H R 100C

in Y cp la c3 3

This study

CY5979

CY4434

Y H R 100C

in Yep la c 3 3

This study

This study

CY5967

M A T a u ra 3 A 0 h is3A 0 leu 2 A 0 t r a l L 37 3 3 A -H IS 3

Y H R 100C

in Y cp la c3 3

Winzeler,
1997
Winzeler,
1997
Winzeler,
1997
This study

CY4400

M A T a u ra 3 A 0 h is3AO leu 2A 0 t r a l F 37 4 4 A -H IS 3

Y H R 100C

in Y cp la c3 3

This study

Y H R 100C in Y cp la c3 3
Isogenic to CY4400 except tti2 F328S
Y H R 100C in Y cp la c3 3
CY5685
Isogenic to CY5684
Y H R 100C in Y cp la c3 3
Isogenic to CY4400
CY5686
1 Y C plac22n : Y C p la c2 2 except TRP1 marker has been switched for U RA3

This study

BY4282

Isogenic to BY4741 except
a d a 2 ::kan*

BY7143

Isogenic to BY4741 except
e a fl:: kan*

BY2940

Isogenic to BY4741 except
ea f7 \\ kan*

CY5684

This study
This study

Table S2: Oligonucleotides used in this study
Name
4292-1
5632-1
5759-1

4479-1
1880
1881
6076-1
6076-2
6108-1
6108-2
6078-1
4225-1

Sequence (5’ to 3’)
ATGATCAATAACGCTACT
CCTCACAAAATCC
CACGTCTGTTCTTGCTGC
ATAAGAATGCGGCCGCTT
TGTTGGCGCCTTATATAA
G
ATACGAGCTCTTTGAGGC
TTTCTCTACCTTC
GGCCCATCACCATCATCA
CCATGC
GGCCGCATGGTGATGATG
GTGATG
ACTGTGGACGTAAGAACG
TG
TGGATCTCCATTTTGCCTC
C
GTATGGCGGTCGTTTCAC
CGTC
CTGGCGATCCTTTCTGTCT
TAGG
AGACGTCGCGCTATACAG
TTCAATCTACCAAT
TTTCATATGGAAATCTTG
AGGG

Description
Forward primer to verify tralLA
Reverse primer to verify traliA
Forward primer to amplify PI3K and
FATC domains of TRAl
Reverse primer to amplify 3’ end of
TRAl
Oligonucleotide to make 6HIS tag
Oligonucleotide to make 6HIS tag
Forward primer to confirm nam7w-uM
Reverse primer to confirm nam7w-UM
Forward primer to amplify 1DH1
Reverse primer to amplify 1DH1
Forward primer to amplify portion of
TRAl
Reverse primer to amplify portion of
TRAl

Table S3: DNA constructs used in this study
Name
CB1503
pS14
pS17
pS26
CB1997
YEplacl95
CB1617

Description
PH 05- LacZ
MET3 - Myc9 - NGG1 in YEplacl95
MET3 - Mycç -TRA1^yìyu¥\ ic in YEplacl95
MET3 - Myc9 - 6HIS-77L47Pbk/fatc in YEplacl95
MET3 - Myc9 - NGG1
Multi-copy shuttle-vector plasmid containing URA3 (Gietz, 1988)
YCPlac33-77M/
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Figure SI: PCR confirming presence of L3733A mutation in suppressor strains.
DNA from CY2706 {TRAI), CY4018 (tralLA ), CY5579 (es2 trai la), CY5580 (esl2
trai la), CY5581 (es35 trai u ) , CY5582 (es36 trai la), CY5583 (es37 trai la), CY5584
(es38 trai la), CY5585 (es39 trai la), CY5586 (es40 trai la), CY5587 (es41 trai la),
CY5588 (es42 trai la), and CY5750 {es43 trai la), was amplified by PCR. Forward
primer 4292-1 and reverse primer 5632-1 containing a mismatch to the leucine codon at
nucleotide position 11197-11198 of TRAI and a match to alanine, were used to confirm
the presence of a 512 base pair PCR fragment. PCR products were separated on a 1 %
agarose gel electrophoresis and visualized under UV after ethidium bromide staining to
check for the desired band. No fragment is seen for the water control (FhO) and a very
faint band is seen for the negative control containing DNA from TRAI (-). PCR
fragments corresponding to 512 base pairs are seen for: the positive control trai la (+),
and suppressors es2 tr a h A (1), esl2 tra^A (2), es35 tra llA (3), es36 tralLA (4), es37
trai la (5), es38 trai la (6), es39 trai la (7), es40 trai la (8), es41 trai la (9), es42 trai la
(10), and es43 trai la (11).
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♦get

the

number

of

elements

in

the

SET

samples
samples

array

N S E T = ( $ { ♦ S E T [0]})
♦

♦these

are

the

chromosome

names

as

they

appear

in

the

bowtie

output file
CHR=(NC_001133 NC_001134 NC_001135 NC_001136 NC_001137 NC_001138
NC_001139 NC_001140 NC_001141 NC_001142 NC_001143 NC_001144
N C _ 0 0 1 145 N C _ 0 0 1 146 N C _ 0 0 1 1 4 7 N C _ 0 0 1 1 4 8 )
♦and the n u m b e r of c h r o m o s o m e s

NCHR=( $ { ♦ CHR[ @] } )
♦
♦♦♦♦♦♦♦♦♦♦

PROGRAM

STARTS

HERE

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

♦

♦♦♦♦♦♦♦♦♦♦
♦♦♦♦♦♦♦♦♦♦
exist

MAKE the BOWTIE C O L O R S P A C E
Do this o n c e o n l y so c h e c k

i f [ - e $ I D X . l . e b w t ]; t h e n
echo "index files exist"
else
bowtie-build
fi
♦♦♦♦

run

-f

through

-C

yeast.fsa

each

name

in

$IDX

the

set

INDEX
to see

if

they

already
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for

((

i=0;

i<=$NSET;

i+ +

));

do
#base

directory

for

this

sample

D I R = (${S E T } _ f o r w a r d _ d i r )

#this sample
S A M P L E = ( ${S E T })
#set up the d i r e c t o r y s t r u c t u r e
# e a c h b a m file g o e s in its own d i r e c t o r y

named

X_var_dir

done
i f [ - d $ D I R ]; t h e n
echo $DIR exists
else
echo making
mkdir $DIR
echo

fi
"running

##########
##########
##########
##########

set

$DIR

$SAMPLE"

MAP

the reads using bowtie
Do this o n c e o n l y
I N P U T is C S r e a d s , C S q u a l i t y
O U T P U T is t o m a p _ b e s t _ S A M P L E . o u t

echo "mapping with bowtie"
$ F A S T A $ S A M P L E .c s f a s t a - f - C

-2

$ F A S T A 1 $ S A M P L E .c s f a s t a

$ Q U A L $ S A M P L E .q u a l — Q 2 $ Q U A L 1 $ S A M P L E .q u a l
$ D I R / m a p _ b e s t l _ t i m e _ $ S A M P L E .o u t
b o w t i e - S - C - v 3 - t $ I D X - f $ F A S T A $ S A M P L E .c s f a s t a
$ Q U A L $ S A M P L E .q u a l $ D I R / m a p _ b e s t l _ $ S A M P L E .o u t

— Q1

-Q

b o w t i e -S - C - 3 10 - - b e s t - M 1 - v 3 - t $ I D X - f
$ F A S T A 1 $ S A M P L E . c s f a s t a - Q $ Q U A L 1 $ S A M P L E .q u a l
$ D I R / m a p _ b e s t 2 _ $ S A M P L E .o u t
# U s e - f t o s p e c i f y t h e f a s t a . c s f a s t a f i l e s a n d - Q (for u n p a i r e d
r e a d s ) o r — Q 1 / - - Q 2 (for p a i r e d - e n d r e a d s )
#to s p e c i f y the c o r r e s p o n d i n g _ Q V . q u a l files.
#— S m e a n s to p r i n t in S A M f o r m a t a n d -C m e a n s c o l o u r s p a c e
# - 3 f o r p a i r e d - e n d a l i g n m e n t s ( o n l y u s e s e b w t .3 a n d e b w t . 4 )
# - - b e s t a n d -M 1 m e a n to r e p o r t o n l y the b e s t a l i g n m e n t a n d not
more than
# w c -1 t o
# - 3 10 t o

one alignment
c o u n t n u m b e r of re a d s
t a k e 10 n t o f f C - t e r m i n u s

e c h o "be g i n n i n g s o r t i n g - be
# e x t r a c t out e a c h c h r o m o s o m e
for

(( j = 0 ; j < $ N C H R ; j + +

));

patient!"
for sorting

do

#set the name
C H R O M = $ {C H R [$j ]}
$DIR/map

e c h o " d o i n g $ C H R 0 M $ N C H R on
bestl trimlO $SAMPLE.out"
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echo

"saving

to

##########

$DIR/$SAMPLE$CHROM.out"

EXTRACT

OUT

EACH

CHROMOSOME

OR

FASTA

FILE

SO TH E Y CAN BE S O R T E D I N D I V I D U A L L Y
# # # # # # # # # # T H I S IS M O R E E F F I C I E N T T H A N S O R T I N G I N O N E B I G F I L E
a w k - v C H R = $ C H R O M '$3 - C H R* $ D I R / m a p _ b e s t l _ $ S A M P L E .o u t
>

$ D I R / $ S A M P L E $ C H R O M .o u t

#The

3rd

exact

column

contains

the NC

number.

Use

~ because

its

not

an

match

##########

SORT

READS

IN E A C H

FILE

SEQUENTIALLY,

4 numerically
sort -k 4 , 4n $ D I R / $ S A M P L E $ C H R O M . o u t
$ D I R / s o r t e d _ $ S A M P L E $ C H R O M .o u t

4,

4n m e a n s

sort

column

>

########## MERGE THE SORTED FILES by appending
c a t $ D I R / s o r t e d _ $ S A M P L E $ C H R O M .o u t »
$ D I R / s o r t e d _ $ S A M P L E .o u t
rm

$ D I R / s o r t e d _ $ S A M P L E $ C H R O M .o u t

rm

$ D I R / $ S A M P L E $ C H R O M .o u t

#done
echo "done

sorting"

#
#add

the

header

information

to

the

sorted

sam

files,

need

first

18 l i n e s
h e a d - n 18 $ D I R / m a p _ b e s t l _ $ S A M P L E .o u t > $ D I R / h e a d _ $ S A M P L E .t x t
e c h o " m a k i n g $ D I R / s o r t e d _ $ S A M P L E .s a m "
cat
$ D I R / h e a d _ $ S A M P L E .t x t $ D I R / s o r t e d _ $ S A M P L E .o u t >
$ D I R / s o r t e d _ $ S A M P L E .s a m
echo

"converting

to bam"

# c o n v e r t files to B A M for m a t
s a m t o o l s v i e w -bS -o $ D I R / s o r t e d _ $ S A M P L E . b a m
$ D I R / s o r t e d _ $ S A M P L E .s a m
# T h e h e a d e r i n f o r m a t i o n is n e e d e d f o r t h i s s t e p
s a m t o o l s v i e w - b S $ D I R / s o r t e d _ $ S A M P L E .s a m >
$ D I R / s o r t e d _ $ S A M P L E .b a m
#The

-b m e a n s

means
echo

output
"sorting

output
file
bam

-

in b a m
ie:

format,

-S m e a n s

samtools

<in>

<out>

"indexing bam

file"

#

# in d ex

the

in

SAM,

file"

file
$DIR/sorted_$SAMPLE.bam

echo

is

bam

#sort the BAM
samtools sort
sort

input

BAM f i l e

$DIR/bamsorted_$SAMPLE

-o
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samtools

index

$DIR/bamsorted_$SAMPLE.bam

## " r u n n i n g p i l e u p "
samtools pileup -vcf yeast.fsa
$ D I R / r a w _ p i l e u p _ $ S A M P L E .t x t

$DIR/bamsorted_$SAMPLE.bam

s a m t o o l s . p l v a r F i l t e r $ D I R / r a w _ p i l e u p _ $ S A M P L E .t x t
> $ D I R / f i l t e r e d _ p i l e u p _ $ S A M P L E .t x t
#Phred quality score
# V C F is v a r i a n t c a l l

a b o v e 20
format

are

filtered

| awk

>

f$ 6 > = 2 0 f

out

#
e c h o " c l e a n i n g up"
rm
$ D I R / h e a d _ $ S A M P L E .t x t
r m $ D I R / s o r t e d _ $ S A M P L E .o u t
done

Figure S2: Shell Script to map colourspace reads to the SGD yeast genome. Bowtie
was used to map reads to yeast genome, and a list of filtered polymorphisms with Phred
score above 20 was obtained (sam variants.sh). This script was written by Dr. Greg
Gloor, and modified by Stephanie Kvas.
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# ! / u s r / b i n / e n v p e r l -w
use strict; #enforces good pr o g r a m i n g
use

practices

warnings;

=com
This

program

literally

compares

FILE2

to

FILE1

and makes

a

third

f i l e c o n t a i n i n g t h e d i f f e r e n c e s in F I L E 2 n o t f o u n d in F I L E 1 .
T h i s p r o g r a m w i l l be u s e d to c o m p a r e the p o l y m o r p h i s m s b e t w e e n
w i l d - t y p e w h o l e - g e n o m e sequencing data and the suppressors.
Therefore,
candidate

this

will

be

used

to

narrow

down

the

number

of

polymorphisms.

=cut
my
my

$ f i l e n a m e = $ A R G V [ 0 ] ; # s p e c i f y f i r s t f i l e t o c o m p a r e to
$ f i l e n a m e 2 = $ A R G V [ 1 ] ; ttspecify s e c o n d f i l e t o c o m p a r e to

my

$outfile

=

$filename

my

%results

=

();

open

FILE1,

while(my

. "_final.txt";

"$filename"

$line

=

$ r e s u l t s {$ l i n e } =

or

die

#Thefinal

file

"$!\n";

<FILE1>){
1;

}
close(FILE1);

open

FILE2,

"$filename2"

w h i l e ( m y $line =<FILE2>)
•$r e s u i t s { $ l i n e } ++;

or

die

"$!\n";

{

}
c l o s e ( F I L E 2 );
open

(OUTFILE,

" > $ o u t f i l e ” ) or

f o r e a c h m y $ l i n e (ke ys
p r i n t O U T F I L E $ l i n e if

die

"$!\n";

%results)
{
$ r e s u l t s {$ l i n e } = =

2;

}
c lo se

OUTFILE;

Figure S3: Perl script to eliminate background polymorphisms. Background
mutations found in wild-type samples were eliminated (Comparisons.pl). This script was
written by Stephanie Kvas.
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#!/usr/bin/env
use

perl

-w

strict;

#read file
my $rfile = $ARGV[0];
ttfeature t a b l e
my $ftfile = $ARGV[1];
ttheader f o r t h e o u t p u t
my $header = $ARGV[2];
#the
my

number

$r

=

of

this

is

the

set

iterations

$ARGV[3];

#hash of array
my %freads;
my
my
my

table,

of

reads,

keyed by

node

%rreads;
%wt;
%mut;

###Pull
open

out

the

information

of

interest

to m e # # # #

(IN, "< $ r f i l e " ) o r d i e " $ ! \ n " ;
w h i l e ( d e f i n e d ( m y $1 = < I N > ) ){
c h o m p $1;
m y @1 = s p l i t A t / , $1;

#
#
#

$ f r e a d s { $ 1 [0 ]} ■ } C$1tl] ] = $1[2]
$ r r e a d s { $ 1 [0 ]) ■ } t $ i [ i ] ] = $1[3]
$ r e a d s { $ 1 [ 0 ] } } t$i[i] ] == $1 [3] ;
$1[2] ;
00

1
—1

vy

$ w t {$1 [0]} } =
$ m u t {$1 [0]} )

II

${
${
${
${
${

}
close IN;
m y 0data;
# r u n t h r o u g h all f e a t u r e t a b l e s in the set
# o u t p u t is b y r e d i r e c t i o n
o p e n (IN, "< $ f t f i l e " ) o r d i e " $ ! \ n " ;
w h i l e ( d e f i n e d ( m y $1 = < I N > ) ){
c h o m p $1;
p u s h 0 d a t a , $1;

}
close
for(my

$i
my
my

=

0;

IN;
$i

<

0data;

$i++){

$1 = $ d a t a [ $ i ] ;
$ln = $data[$i+l];

#print "$l\t$ARGV[2]_fwdr\t$ARGV[2]_revr\n” if ($1 =~

/"#/);
if

($1

!~
my

/A# / ) {
01

$ 1[ 2 ]

=
=~

split/\t/,
s / \ D / /;

$1;

$ 1 [3 ]

=-

s/\D//;
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my

$max

=

$1[2];

my

$ m a x = $1 [3] i f $1
$ m i n = $ 1 [ 2 ] i f $1
m y $fr = m y $rr =
f o r ( m y $i = $ m i n ;
${

$min

[3] >
[2] <
0;
$i < =

=

$1[3];

$max;
$min;
$max;

$i++){

$fr

+=

${

$ f r e a d s {$1[1]}

} [$i ] if

exists

$rr

+=

${

$ r r e a d s {$1[1]}

} [$i ] if

exists

$ f r e a d s {$1 [1

]} } [$ i ] ;
${

$ r r e a d s {$1 [1

]} } [ $ i ] ;
}
# p r i n t ” $1 [ 0 ] \ t $ l [1 ] \ t $ l [ 1 ] \ t $ l [ 2 ] \ t $ l [ 3 ] \ t $ f r \ t $ r r \ n ” if
0; # w o r k s
#print "$l\t$fr\t$rr\n"

$r

==

if

$r

#now find in t e r g e n i c reads
m y @ l n = s p l i t / \ t / , $ln;
m y $ maxln = $1[2]; m y $minln
$maxln
$minln

=
=

$1[3]
$1 [2]

if
if

$1[3]
$1 [2]

>

=

[1]}

not

work

$1[ 3 ] ;

$i++){

$ f r l n += ${ $ f r e a d s { $ 1 [ 1 ] }

} [$i]

if

$rrln

} [ $ i ] if

$freads{$l

} [ $ i ];

exists
[1]}

${

#Does

> $maxln;
< $minln;

m y $ f r l n = m y $ r r l n = 0;
f o r ( m y $i = $ m a x ; $i < $ m i n l n ;
exists

0;

${

+=

${

$ r r e a d s {$1[1]}

$rreads{$l

} [$i];

}
#print "$l[0]\t$l[1 ] \ t $ l [1 ]\ t $ l [ 2 ] \ t $ l [3]\ t $ f r l n \ t $ r r l n \ n " if
r = = 0;
#print "$l\t$frln\t$rrln\n"

$
if

$r

> 0;

}
Figure S4: Perl script to assign gene names and descriptions to each polymorphism
(add_reads_to_features.pl). This script was written by Dr. Greg Gloor with slight
modifications made by Stephanie Kvas.

